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Abstract 
Undernutrition is an outcome of insufficient food intake and repeated infectious diseases. 
Lipid-based nutrient supplements (LNS) are calorie and nutrient dense food products that are 
suitable to complement most food rations due to their long shelf life and convenience. Although 
available in other markets, staple-based LNS for India do not exist. More importantly, no currently 
available LNS formulations address the other immediate causes of undernutrition such as parasitic 
infections and gut inflammation in children. The objective of this study was to develop advanced 
LNS 2.0 with improved shelf stability, consumer acceptability, and antiparasitic activity via added 
oregano essential oil (OEO) bioactives.  
LNS were formulated using Indian staple dairy ingredients, and optimized using Response 
Surface Methodology (RSM) via face centered composite design with four factors and three coded 
levels: antioxidant (ascorbyl palmitate; at 0.0, 0.01, 0.03%), emulsifier (soy lecithin; at 0.5, 1.0, 
1.5%), omega-3 (flaxseed oil (FO); at 0, 5, 10%) and accelerated storage temperature and time (23 
and 40±2°C; at 0, 3, 6 months). Consumer acceptability was assessed using a 9-point hedonic scale 
among Indian mothers and students. Next, a dual modality in vitro cell culture model was 
employed to investigate the effect of OEO and its main bioactive carvacrol on prevention of 
parasite C. parvum invasion and infection of HCT-8 cells. Finally, β-Cyclodextrin (β-CyD)  
encapsulation of OEO and carvacrol (1:1 molar) was utilized to mask the potent flavor of 
bioactives, and achieve controlled intestinal delivery of bioactives, measured using triangle 
sensory test and 2-phase in-vitro digestion model, respectively.  
Optimal levels to maximize storage time and flaxseed oil and minimize oxidation were 
found as 0.02% antioxidant 1.5% emulsifier, and 4.9% FO. LNS formulations were found 
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acceptable with or without FO similar to other commercial supplements. OEO and carvacrol were 
found to reduce relative C. parvum infectivity in a dose-dependent manner to 55.6 ± 10.4% and 
45.8 ± 4.1% at 60 and 30 μg/mL of OEO and CV, respectively. Lastly, β-CyD complexes of OEO 
and CV were found significantly stable (p<0.05) through the gastric and intestinal phase enabling 
their potential release in colon via fermentation by colonic microflora. Triangle tests revealed no 
significant difference in color, smell, and taste between LNS with and without β-CyD-OEO 
complexes. In conclusion, staple-based LNS functionalized with β-CyD-OEO complex were 
feasible and can potentiate their application in addressing undernutrition and parasitic infections 
in at-risk populations. 
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Chapter 1: Introduction 
1.1 Malnutrition in India 
 Child undernutrition is a major cause of morbidity and mortality in young children (<6 
years) and remains pervasive in low and middle-income countries such as India. Nearly half of all 
deaths in children under 5 are attributable to undernutrition, translating into an unnecessary loss 
of about 3 million children per year (UNICEF/WHO/World Bank Group, 2016). In India, 
undernutrition afflicts 1 in 2 children, where 43% (57 million) and 48% (68 million) of children 
under five are underweight and stunted, respectively (NFHS, 2007). About 9 million children in 
India suffer from severe acute malnutrition, which is defined as severe wasting with visual 
nutritional edema - very low weight-for-height or <-3 Z-scores of the median WHO growth 
standards. A larger number, 20 million, suffer from moderate acute malnutrition, which is defined 
as wasting with low weight-for-height or >-3 and <-2 Z-scores of the median WHO growth 
standards or mid-upper arm circumference between 11 and 12.5 cm. A significant 5 million 
children die every year as a direct or indirect result of undernutrition (NFHS, 2007). Undernutrition 
has severe consequences on academic performance, future work productivity, potential income 
and susceptibility to chronic diseases (Black et al., 2013). According to the UNICEF framework, 
the two immediate causes of undernutrition are inadequate dietary intake (quantity and quality of 
food) and repeated infectious diseases such as parasitic infections (Black et al., 2008). Both of 
which are interrelated and are found to impair the immune system interdependently, forming a 
vicious infection-malnutrition cycle (Hughes and Kelly, 2006) (Figure 1) 
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Problem 
Nutrition Gaps - In India, supplementary feeding programs are widely used to address 
undernutrition in children from 6 – 72 months via the Integrated Child Development Service. 
Under these programs the children are entitled supplementary nutrition via hot cooked meal at 
Anganwadi Centers (day care centers) and/or take home rations such as mixed flours (sattu), 
sweets (sheera), and porridge (upma), or sometimes raw ingredients such as rice and pulses (ICDS, 
2014). Although such interventions have been useful in improving some health outcomes, 
increasing children enrolment and reducing gender bias, there are still issues with nutritional 
adequacy and consumption compliance due to the low acceptability of products, and additional 
food preparation requirements (Lokshin et al., 2005). Moreover, some food rations contain 
insufficient nutrients to meet program goals (Bhagwat et al., 2014; Varma et al., 2007). Thus, a 
low cost, nutritious, palatable, ready to use food prepared using staple ingredients that could be 
included in the daily meals of children at schools or supplementary feeding centers in India is 
needed. 
 Repeated enteric parasitic infection and gut inflammation - Enteric parasitic 
infections are prevalent in children (<5 years) living in low-income settings, especially in countries 
such as India, owing to inadequate sanitation, hygiene and healthcare system and their less 
developed immune systems (Scrimshaw, 1994). These infections alter the epithelial integrity and 
weaken the immune system in children resulting in reduced nutrient digestion and absorption, 
chronic gut inflammation, iron deficiency anemia, protein-energy malnutrition, and reduced 
growth and cognitive development (Katona and Katona-Apte, 2008). This is further worsened by 
the existing increased levels of proinflammatory prostaglandins in Indian populations due to the 
high ω6:ω3 ratios of the vegetarian diets (30:1 to 70:1) (Abedi and Sahari, 2014). The lower ω6:ω3 
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ratio is recommended not only for normal growth, cell functioning, and immune function, but also 
for adequate anti-inflammatory response (Brenna et al., 2015; Calder, 2006). Thus, interventions 
focused on both providing adequate nutrition and addressing parasitic infections and gut 
inflammation in children are needed to effectively address the multietiological problem of 
undernutrition (Egger et al., 1990). 
Opportunity 
 Indian lipid-based nutrient supplement - Lipid-based nutrient supplements (LNS) are 
fortified food products, containing concentrated nutrients (energy, protein, essential fatty acids, 
and micronutrients) and are suitable to complement most food rations, due to their longer shelf life 
and convenience (Arimond et al., 2013). Existing LNS such as Nutributter®, PlumpyDoz® and 
PlumpySup® (Nutriset, 2015) have been tested and proven successful in improving growth 
outcomes in children (Adu-Afarwuah et al., 2007; Phuka et al., 2008). Nonetheless, they have not 
been accepted in India mainly due to problems associated with high cost, poor acceptability, 
foreign import, safety and sustainability (Arie, 2010). Similar peanut-based LNS were not well 
accepted by pregnant and lactating women in Bangladesh (Ali et al., 2013), and by undernourished 
children in India (Dube et al., 2009). The World Food Program (WFP) and local doctors have 
expressed an urgent need for development of indigenous and low-cost LNS to address 
undernutrition in India (Gupta et al., 2006) 
LNS specifications on nutritional composition, processing and microbiological standards 
provided by World Food Program (WFP) and other organizations allow easy manipulation of 
ingredients so these can be modified to staple ingredients from India, with lower ω6:ω3 fatty acid 
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ratio, and even functionalized to include antiparasitic ingredients (Jelensperger, 2016; Chaparro 
and Dewey, 2010). 
 
1.2 Long-term Goal, Research Objective, and Hypothesis 
 The long-term goal of this project is to holistically address the multi-etiological problem 
of undernutrition through functional foods designed to provide benefits beyond the basic nutrition. 
The objective of this research, which is the next step towards accomplishing this long-term goal, 
is to develop an advanced LNS 2.0, which is nutritious, stable, and highly palatable, complemented 
with the effective dose of cyclodextrin-included oregano essential oil (OEO) to address the 
immediate causes of undernutrition including dietary intake of quality nutrients and gut 
inflammation originated from parasitic infections in children. The central hypothesis is that OEO 
and CV will reduce the Cryptosporidium parvum (C. parvum) invasion of HCT-8 cells in vitro and 
inclusion of bioactives in β-cyclodextrin (β-CyD) complexes will improve their stability, enabling 
their functional activity in the colon, as evaluated in simulated digestion conditions. The 
hypothesis will be tested by investigating three specific aims:  
Specific Aim 1. Development of an Omega-3 fortified lipid-based nutrient supplement using staple 
ingredients from India. The working hypothesis is twofold: 1) Response surface methodology 
(RSM) optimization will pinpoint the adequate levels of flaxseed oil, antioxidant and lecithin 
ingredients in LNS, which will result in lower oxidation during storage. 2) LNS products with 
flaxseed oil (10% of the final weight) will have similar consumer acceptability to the other existing 
LNS and supplementary feeding products in India, among Indian mothers and students. 
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Specific Aim 2. Evaluate the effectiveness OEO and CV against C. parvum using the HCT-8 cell 
model. The working hypothesis is that OEO and its principal component CV will reduce C. parvum 
invasion and infection at concentrations well tolerated by the HCT-8 cell monolayers.  
Specific Aim 3. Preparation of β-cyclodextrin (β-CyD) inclusion complexes of CV and OEO, in 
vitro characterization of digestive stability and bioaccessibility, and sensory evaluation of LNS 
with β-CyD-OEO complexes. The working hypothesis for this aim is twofold: 1) β-CyD inclusion 
will mask the potent unpleasant flavor of OEO and CV; and, 2) β-CyD inclusions limit the release 
of OEO or CV after 2-phase simulated in vitro digestion conditions, due to the absence of 
microflora during these phases. 
 
1.3 Significance and Rationale 
  This study has both basic and applied significance in LNS research and development, 
natural bioactives, and parasitology and global health initiatives. In the field of LNS, these studies 
will provide a basis for systematic development, characterization and optimization of LNS with a 
focus on a particular target population. In the field of natural bioactives and parasitology, these 
studies will contribute to our limited knowledge of the use of CV and OEO in foods to prevent 
parasitic infections. In the field of global health, these studies will expand our ability to create 
functional LNS products that can include components that better address the immediate causes of 
undernutrition in low-income countries as well as to instigate interest of stakeholders to further the 
research in the area of functional LNS. 
 The rationale for the long-term goal of this research is that LNS designed with Indian 
ingredients and functionalized with OEO can holistically address the challenging problem of 
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undernutrition in India via food-based approach. The rationale for assessing the effect of CV and 
OEO on C. parvum in Aim 2 is that it will enable the establishment of an effective dose needed to 
reduce enteric parasitic infections. The rationale for characterization and inclusion of OEO and 
CV in β-CyD in Aim 3 is that such inclusions will mask the potent flavor and enable controlled 
delivery of bioactives in the lower gut, where parasites usually reside. 
 
1.4 Thesis Structure 
 The thesis is organized into six chapters. Chapter 1 and Chapter 2 are composed of an 
introduction to the thesis and a detailed literature review, respectively, which provide a background 
of each area of research relevant to the dissertation research included herein. This information 
gives the reader sufficient background knowledge to understand the theoretical basis of the 
conducted research. Chapter 3, describes the development of an Omega-3 fortified LNS using 
staple ingredients from India, which is nutritious, stable and acceptable among Indian populations 
(Gaur et al., 2017). These data from Chapter 3 partially satisfy the Aim 1 and provide a basic 
formula for further studies. The research in Chapter 4 describes for the first time the dose-
dependent effect of OEO and CV on the C. parvum invasion and infection of HCT-8 cells. These 
data support the hypothesis of Aim 2 and provides a basis for extrapolation of an effective dose of 
OEO to be added to LNS basic formula. Chapter 5 contributes to completing the overall objective 
of this dissertation creating an LNS 2.0 through the incorporation of OEO in β-CyD inclusions to 
mask the potent flavor of OEO and enable controlled targeted delivery of antiparasitic OEO in the 
lower gut, where the enteric parasites usually reside. Chapter 6 summarizes the findings from each 
of the previous chapters and concludes with the potential future directions of this research. 
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1.5 Figure 
Figure 1. Undernutrition/infection cycle (Schaible and Kaufmann, 2007). 
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Chapter 2: Literature Review 
2.1 Undernutrition 
 Undernutrition, as defined by UNICEF, is an outcome of insufficient food intake 
(hunger) and repeated infectious diseases (Black et al., 2008). Undernutrition occurs in various 
forms including underweight, stunting (low height for age), wasting (low weight for height) and 
micronutrient deficiency (iron, folic acid, vitamin A, zinc and iodine below healthy threshold) 
(Figure 2). Undernutrition is opposite of overnutrition, which is an outcome of excessive intake of 
energy and/or nutrients and includes conditions such as overweight obesity and non-communicable 
diseases such as heart disease, stroke, diabetes and cancer. Young children (<5 years) are most 
vulnerable to undernutrition and nearly half of all deaths in children under 5 are attributable to 
undernutrition, translating into an unnecessary loss of about 3 million children a year 
(UNICEF/WHO/World Bank Group, 2016). Undernutrition is a key underlying factor for under 5 
mortality due to greater susceptibility to infections and slow recovery from illness, creating a 
vicious lethal cycle of worsening illness and deteriorating nutritional status. In addition, it has 
severe consequences on academic performance, future work productivity, potential income and 
susceptibility to chronic diseases (Black et al., 2013). 
 Stunting (height for age below -2z scores of the median WHO growth standards), 
wasting (weight for height below -2z scores of the median WHO growth standards) and 
underweight (weight for age below -2z scores of the median WHO growth standards) are the most 
used anthropometric indicators of child undernutrition and are priority global public health 
problems. Figure 3 shows Waterlow’s classification of the degree of undernutrition (Waterlow et 
al., 1977).  
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According to recent surveys, 159 million and 50 million children are affected by 
stunting wasting worldwide, respectively (IFPRI, 2016). Approximately 800,000 deaths are lost 
due to wasting (60% of which are attributable to severe wasting) and over one million due to 
stunting (Black et al., 2013). Reportedly, wasting and stunting result in loss of 64.6 and 54.9 
million Disability Adjusted Life Years (DALYs) respectively, and account for 14.8% and 12.6% 
of the total global DALYs for children under five (Black et al., 2008). In India alone, undernutrition 
afflicts 1 in 2 children, where 57 million (43%) children under 5 are underweight and 63 million 
(48%) stunted (NFHS 2005-06). Weight for age distribution curves for children (<3 years) in India 
falls to the left of the global reference population as shown in Figure 4 (Bhutia, 2014). Nine million 
children suffer from severe acute malnutrition (severe wasting with visual nutritional edema - very 
low weight for height, below -3z scores of the median WHO growth standards), 20 million from 
moderate acute malnutrition (wasting – low weight-for-height, between -3 and -2 z-scores of the 
median WHO growth standards or mid-upper arm circumference (MUAC) between 11 cm and 
12.5 cm)  and 5 million die every year as a direct or indirect result of undernutrition (NFHS 2005-
06). In India, child undernutrition is declining and partial findings from recent surveys (2015-16) 
show reduction to 38.4% stunted, 21% wasted, 7.5 % severely wasted and 35.7% underweight 
children under 5 (NFHS, 2016). Although, there is a downward trend in child undernutrition in 
India and stunting and wasting rates have declined in the past decade, it still carries the largest 
burden of undernutrition.  
 Undernutrition often starts in utero and can have severe consequences throughout the 
life cycle and can span generations. For instance, undernutrition during pregnancy can have 
serious implications for the developing fetus and for future infant’s morbidity and mortality risk, 
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vision and cognitive development. Figure 5 shows various nutrition problems, causes and 
consequences at various stages of life. The first 1000 days of child’s life are crucial to avoid 
chronic stunting and prevent irreversible damage to child’s brain development and physical 
growth, leading to reduced mental capacity, greater susceptibility to infection and disease and 
long-term loss of earning potential. Thus, proper nutrition and healthcare are essential during the 
formative years of the child.  
 There are several causes of undernutrition at different societal levels as recognized by 
the United Nations Children’s Fund (UNICEF) conceptual framework. (Figure 6). Basic causes 
are influenced by the structure and processes of societies, underlying causes by households and 
communities and immediate causes by individuals (Black et al., 2008). Immediate causes include 
inadequate intake of nutrients and/or repeated infections that could further increase nutrient 
requirements and malabsorption of nutrients consumed, resulting in a vicious infection-
undernutrition cycle (Figure 7). In this thesis our focus is on the immediate causes of undernutrition 
and other causes are discussed in detail by Black et al. (2008). 
 
2.2 Undernutrition and Parasitic Infections 
 Immediate causes of undernutrition, i.e. inadequate dietary intake and repeated 
infectious diseases, such as parasitic infections, are closely related and both are found responsible 
to impair the immune system interdependently (Figure 8) (Hughes and Kelly, 2006; Cunnigham-
Rundles S, 2008). Intestinal parasitic infection is considered as a global public health problem by 
the World Health Organization (WHO), afflicting 3.5 billion people and causing clinical morbidity 
to around 450 million people globally (WHO, 1998). Although it affects all ages and socio-
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economic status, parasitic infections are more prevalent in children (<5 years) living in low-income 
settings, owing to inadequate sanitation, hygiene and healthcare system and their less developed 
immune systems (Scrimshaw, 1994). Enteric parasites result in reduced nutrient digestion and 
absorption (Northrop-Clewes et al., 2001), chronic gut inflammation (Wang, 2008), iron 
deficiency anemia (Farid et al., 1969), protein-energy malnutrition (Muniz-Junqueira and Queiróz, 
2002), reduced growth (Stephenson et al., 1993) and reduced cognitive development (Olness, 
2003) in children. Thus, interventions focused on providing nutritional foods to children are not 
sufficient to tackle the multietiological problem of malnutrition (Egger et al., 1990). 
 Common parasites responsible for morbidity and mortality in children are helminths 
such as Ascaris lumbricoides (roundworm), Trichiuris trichiuria (whipworm), Ancylostoma 
duodenale, and Necator americanus (hookworms) and protozoans such as Giardia intestinalis, 
Entamoeba histolytica, Cyclospora cayetanensis, and Cryptosporidium spp (Figure 9). 
 Subclinical infection with enteric pathogens is common in developing countries, even 
in the absence of diarrhea (Kotloff et al., 2013a). Repeated frequent exposure to enteric pathogens 
due to faeco-oral transmission results in a change of gut structure and function, characterized by 
villous atrophy and chronic inflammation of the small intestine resulting in environmental enteric 
dysfunction (EED). This leads to modest malabsorption and increased intestinal permeability 
(Keusch et al., 2013).  Intestinal permeability can result in translocation of microbial products from 
the gut lumen to the systemic circulation, where they can trigger chronic inflammation suppressing 
IGF-1(Prendergast and Humphrey, 2014). 
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2.3 Current Interventions in India 
 Various government run interventions exist to address undernutrition in India as listed 
in Table 1. Through Integrated Child Development Services (ICDS) the beneficiaries’ i.e. pregnant 
and lactating women and young children, are entitled to supplementary nutrition in the form of 
morning snack (milk/banana/egg/fruits/micronutrient fortified foods) and a hot cooked meal at 
Anganwadi centers (Figure 10). In addition, take-home rations (THR) sattu, sheera, upma or 
sometimes raw ingredients such as rice and pulses are provided to supplement the daily meals of 
children aging from 6 to 72 months. Otherwise healthy children under 6 years receive 12-15 g 
protein and 500 cal energy and undernourished children at a level of 800 kcal, 20 g of protein 
(ICDS, 2014). Beyond providing supplementary nutrition, Anganwadi centers are responsible for 
growth monitoring and identification of moderatly and severely underweight children, nutrition 
and health counseling, pre-school education, and often monthly immunization, micronutrient 
supplementation, deworming, and antenatal care. 
 The foods and take home rations offered through government welfare programs have been 
successful in providing nutrition, improving some health outcomes, increasing children enrolment 
and reducing gender bias. However, they have significant problems with consumption compliance 
due to the poor acceptability of products, and additional cooking requirements for women, which 
leads to the ingredient use for other purposes and consumption of lower quantities than those 
prescribed. Moreover, some food rations contain insufficient nutrients to meet program goals 
(Varma et al., 2007; Bhagwat et al., 2014).  
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2.4 Lipid-based Nutrition Supplements 
 Lipid-based nutrient supplements (LNS) are fortified ready to use food products, 
containing concentrated nutrients (energy, protein, essential fatty acids, and micronutrients) and 
are suitable to complement most food rations (Arimond et al., 2013). LNS are different from ready 
to use therapeutic foods (RUTFs) as outlined in Table 2 and are used for different applications 
ranging from prevention to treatment depending upon the quantity of LNS used.  
The examples listed in Figure 11 are peanut-based RUTF or LNS, first formulated in 
1996 and patented (US 6346284 B1) by André Briend, a French pediatric nutritionist. These 
products are now commercialized by the French company, Nutriset. Products are thick pastes made 
from peanut butter, sugar, vegetable oil, milk powder, and a vitamin/mineral premix with an aim 
to provide energy, proteins, and other nutrients that are needed by malnourished children to recover 
and resume their growth. The low water activity is suitable to store packaged product for up to two 
years at ambient temperatures.  
 Existing LNS such as Nutributter®, PlumpyDoz® and PlumpySup® (Nutriset, 2015)  
(Figure 11) have not been accepted in India mainly due to problems associated with higher cost, 
poor acceptability, foreign import, safety and sustainability (Arie, 2010). Similar peanut-based 
ready to use therapeutic foods (RUTF) were not well accepted by pregnant and lactating women 
in Bangladesh (Ali et al., 2013), and by malnourished children in India (Dube et al., 2009). The 
World Food Program (WFP) and local doctors have expressed an urgent need for the development 
of indigenous and low-cost LNS to address severe and moderate undernutrition in India (Gupta et 
al., 2006). LNS have been used for complementary feeding to address acute malnutrition in 
children and have had mixed results as listed in Table 3: 
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2.5 Omega-3 Fortification 
 Omega-3 long chain polyunsaturated fatty acids are essential fatty acids with an array 
of biological effects in human health and disease. The three principal omega-3 fatty acids are 
alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) and 
are important for a number of bodily functions, including muscle activity, brain development, 
blood clotting, digestion, cell division and overall growth (Yashodhara et al., 2009). They also 
play an important role in the regulation of tissue inflammation and are associated with inhibition 
and/or stimulation of cytokine production. Enteric infection, a trigger for inflammatory response, 
and intestinal inflammation are very common in the malnourished children in India, resulting in 
malabsorption of nutrients (Gupta et al 2011). Omega 6: omega 3 ratio is recommended to be 3:1, 
not only for normal growth, cell functioning and immune function but also for adequate 
inflammatory: anti-inflammatory response (Simopoulos, 2002; Simopoulos, 1991; Brenna et al., 
2015). Currently, no specifications for omega 6: omega 3 ration exists for LNS which allows high 
n-6 polyunsaturated fatty acid (PUFA) content and low n-3 PUFA. 
 Indian population generally being vegetarian have ω6:ω3 ratios of 30:1 to 70:1, which 
results in increased levels of proinflammatory prostaglandins in the body (Abedi and Sahari 
2014). Flaxseed oil is a good source of ALA omega 3 PUFA and have better conversion rates to 
PUFA EPA (anti-inflammatory agent to balance omega 6 arachidonic acid) and DHA (essential 
for neural development) in vegetarian populations (Welch et al., 2010), and has anti-inflammatory 
properties (Caughey et al., 1996).   
 Recently, there has been an increased interest in improving the omega-3 fatty acid 
profile of conventionally used peanut based LNS formulations, which are rich in omega-6 linoleic 
acid (LA) but contain negligible omega-3 alpha linolenic acids (ALA)(Brenna et al., 2015; Hsieh 
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et al., 2015; Jones et al., 2015) (Table 4). In a recent study of children with SAM, a two-month 
supplementation with RUTF high in oleic acid and with a 1:1 LA:ALA ratio increased circulating 
EPA and DHA and reduced arachidonic acid compared to standard RUTF with LA/ALA ratio of 
53:1(Hsieh et al., 2015). In another study, a peanut-based RUTF fortified with FO significantly 
increased plasma EPA and docosapentaenoic acid, but not DHA among children suffering from 
SAM (Jones et al., 2015) These results support the hypothesis that if omega-3 PUFA oral delivery 
is increased, changes in their accumulation will be reflected in the circulation of malnourished 
individuals. 
 
2.6 Cryptosporidium parvum Characteristics and Reproduction 
 Cryptosporidiosis, caused by a protozoan parasite of the genus Cryptosporidium, is the 
second largest cause of diarrheal disease and death in infants after rotavirus, (Kotloff et al., 2013b). 
It is the leading cause of infectious diarrhea in Indian children with positive rates of 1.1 to 18.9% 
(Ajjampur et al., 2008). It is excreted in the feces of an infected host in the form of an oocyst and 
is mainly transmitted from person to person, animals and indirectly through the environment 
(water and food)(Daniels et al., 2016). The thick-walled oocyst is environmentally resistant and 
does not decay in the environment as well as in most disinfection processes, making it highly 
resilient (Smith et al., 2005). 
 Humans are most frequently infected with C. hominis and C. parvum and both 
anthroponotic and zoonotic cycles have been documented in the life cycle of these parasites (Smith 
et al., 2005). C. parvum, a monoxenous apicomplexan mucosal parasite, has gained wide 
recognition due to its association with a severe diarrheal disease that affects mostly infants and 
children who are immunocompromised and undernourished. C. parvum does not multiply outside 
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of the host and completes all stages of its development (asexual and sexual) within a single, live 
host, however, it could only complete its asexual cycle in vitro. C. parvum infection initiates after 
ingestion of thick-walled oocysts, which are inactive in the stomach and upper intestine, but excyst 
in the gastrointestinal tract to release four infective sporozoites (Figure 12). These motile 
sporozoites then attach to the receptors on the apical membrane of host epithelial cell, mediated 
by carbohydrate: lectin interactions, and induce reorganization of host-cell actin cytoskeleton and 
protrusion of the host-cell membrane around the sporozoite to form a parasitophorous vacuole. 
The proteins involved in the parasite attachment to host cells are either present on the surface or 
exocytosed from the parasite via specialized secretory vesicles; micronemes, rhoptries, and dense 
granules (O’Hara and Chen, 2011). Here, the organism remains intracellular but extracytoplasmic. 
The internalized sporozoite further matures and undergoes series of asexual and sexual 
reproduction (schizogony) to produce oocytes. The two morphologic forms of the oocysts are thin-
walled oocysts (asexual stage), which excyst within the same host (causing self-infection), whereas 
the thick-walled oocysts (sexual stage) are shed into the environment from fecal excretion (Chen 
et al., 2002).  
 Studies on genome analysis of C. parvum have revealed that the parasite relies solely 
on the host for nutrient acquisition as it lacks enzymes for Kreb’s cycle and depends largely on 
glycolysis for energy requirements. It also lacks the capacity for the de novo synthesis of amino 
acids, fatty acids and nucleosides. It is speculated that C. parvum encodes an extensive array of 
transporters to transfer and acquire nutrients from the host (Xu et al., 2004). 
 As discussed earlier, undernutrition and parasitic infections are interrelated and can have 
an additive negative effect on growth outcomes of undernourished children. This relationship was 
found true and additive in undernourished suckling mice infected with C. parvum oocytes during 
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the first 2 weeks of life, analogous to the first postnatal year in humans. Undernutrition intensified 
C. parvum infection and mucosal damage in mice, conversely, C. parvum infection solely caused 
undernutrition and growth reduction in nourished mice. A synergistic effect between infection and 
undernutrition was seen in infected undernourished mice which exhibited higher oocyst shedding, 
greater mucosal damage in terms of blunted villi and deeper crypts, increased mucosal 
inflammatory TNF-α and IFN-γ intestinal levels, higher mRNA expression and severe enteropathy 
compared to nourished uninfected mice (Coutinho et al., 2008).  
There are a few compounds with some, albeit limited, anticryptosporidial activity among 
them are paromomycin, nitazoxanide, azithromycin in combination with paromomycin, 
roxithromycin, and protease inhibitors often used in highly active antiretroviral therapy (Gargala, 
2008). Currently, only one FDA-approved, moderately effective drug, nitazoxanide (Alinia®) 
(Miyamoto and Eckmann, 2015), is available for treatment of Cryptosporidium infection. Due to 
increasing resistance and severity of side effects, new alternative bioactives are currently under 
examination (Anthony et al., 2005).  
 
2.7 Oregano Essential Oil 
Plant-derived essential oils, which are lipophilic, volatile plant compounds, primarily 
composed of monoterpenes and sesquiterpenes, have been used since ancient history and have seen 
a rapid resurgence in the recent years (Little and Croteau, 1999; Kelly et al., 2005). Essential oils 
of thyme, clove, sage, turmeric, oregano are known to exhibit antibacterial and antiparasitic 
activity (Anthony et al., 2005). Oregano Essential oil (OEO), also known as the Mediterranean 
miracle, Sathra in Ayurveda or Himalayan Marjoram in India, is known to possess antibacterial, 
20 
 
antiviral, antifungal, antiparasitic and antioxidant activities (Burt, 2004). OEO is extracted through 
steam distillation, cold solvent extraction, supercritical fluid extraction or microextraction of plants 
from Origanum genus, of which Origanum vulgare subsp. hirtum is the most common varied due 
to its high quality and yield (Kintzios, 2002). In India, oregano is found in the temperate Himalayas 
from Kashmir to Sikkim. The principal components responsible for the bioactivity of OEO are 
carvacrol (CV) and thymol (Burt, 2004) (Figure 13).  
OEO and CV are considered as generally recognized as safe (GRAS) by FDA for food use 
and are also included in the Council of Europe in the list of chemical flavorings that can be added 
to foods (De Vincenzi et al., 2004). In addition, they are found to be non-toxic at the high dose in 
a short term study (Force et al., 2000). Most of the knowledge on OEO and CV effectiveness 
against parasites, their safety, and other side effects has been generally acquired through word of 
mouth or folklore. As of our knowledge, no literature or data is available on its potential bioactive 
use in a food supplement.  
 The mode of action of OEO and its constituents is not clear but is attributed to the 
presence of hydroxyl group in the phenolic compounds carvacrol and thymol (Ultee et al., 2002) 
and their hydrophobicity (Burt, 2004), which allows the essential oils to penetrate the cell 
membrane and reduce parasitic infection by affecting cytoplasmic metabolic pathways or 
organelles (Santoro et al., 2007). In addition, monoterpenes such as CV can modify the calcium-
dependent protein kinase 1 (CDPK1) and affect the Ca2+ mediated signaling of the parasite, 
required for invasion, differentiation and regulation of other vital functions (Nagamune et al., 
2008; Murphy et al., 2010). In addition, the hydrophobicity (Burt, 2004) and presence of hydroxyl 
group in CV and thymol (Ultee, Bennik, & Moezelaar, 2002), may allow the phenols to penetrate 
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the cell membrane and reduce parasitic infection by modulating cytoplasmic metabolic pathways 
such as ATP synthesis (Turina et al., 2006; Santoro et al., 2007). 
 
2.8 Encapsulation 
 Incorporation of OEO or its constituents in food is a challenging task due to its high 
volatility, instability, interaction with food ingredients, and potent flavor. These compounds have 
extremely low flavor threshold, evaporate easily, and decompose and oxidize during formulation, 
processing and storage due to exposure to heat, pressure, light, or oxygen (Beirão-da-Costa et al., 
2013; Hosseini et al., 2013). Moreover, their therapeutic effect against parasites might be limited 
by their rapid metabolism and instability during digestion. Thus, a small fraction of the oral dose, 
if any, reaches the lower gut, where these parasites reside (Kohlert et al., 2002; Kohlert et al., 
2000). Encapsulation is a widely used technique for improving stability, controlled delivery and 
reducing the unpleasant odor and taste (Wang et al., 2009; McClements et al., 2009). Materials 
such as chitosan nanoparticles (Hosseini et al., 2013), tween 80 (Bhargava et al., 2015), milk 
powders (Baranauskienė et al., 2006), gelatin/sucrose microparticles (Beirão et al., 2004), 
sorghum/rice starch (Almeida et al., 2013), liposomes (Liolios et al., 2009), and cyclodextrins 
(Guimarães, Oliveira, Alves, Menezes, Serafini, Araújo, et al., 2015) have been used to improve 
functionality and stability of OEO or carvacrol.  
Of all the available materials, cyclodextrin is the one of the few materials that is GRAS 
certified by FDA and Food Safety Standards Authority of India and has been reported successful 
in improving stability and solubility of essential oils, masking of unpleasant odor and taste and 
achieving controlled gut delivery (Wang et al., 2009; McClements et al., 2009) (Szente and Szejtli, 
2004). In addition, cyclodextrins have been shown to treat C. parvum infections in lambs and 
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calves at a dose of 500 mg/Kg (Castro-Hermida et al., 2001; Castro-Hermida et al., 2002; Castro-
Hermida et al., 2000).  
Cyclodextrins (CyD) (α, β, and γ) are cyclic oligosaccharides with six to eight glucose units 
joined by α-1,4 glycosidic bonds and have a rigid structure with a hydrophilic outer surface and a 
singular hydrophobic cavity due to the absence of hydroxyl group (Szente and Szejtli, 2004) 
(Figure 14). CyDs are produced from starch (e.g., corn, potato, maize, and wheat.) and related α-
1,4-glucans via enzymatic conversion – degradation and cyclization – using CyD 
glycosyltransferase (CGTase) and, partly, α-amylases. Due to their unique structure, CyDs are 
used to form inclusion complexes with hydrophobic compounds. CyDs are neither hydrolyzed nor 
absorbed in the stomach and small intestine, but are broken into small mono- and oligo-saccharides 
in the large intestine by colonic bacteria (approx. 1011 – 1012 CFU/mL), especially Bacteroides, 
using them as sole carbon source and by the stimulation of cyclodextranase activity by exposure 
to CyDs (Antenucci and Palmer, 1984)(Sinha and Kumria, 2001). This makes them excellent 
carriers for localized drug delivery to the colon, as they remain intact through the stomach deliver 
colon specific drugs, specifically targeted to gut parasites such as C. parvum. There are no toxic 
effects associated with oral administration of CyDs. These are not absorbed across the 
gastrointestinal tract due to their chemical structure (large number of hydrogen donors and 
acceptors), their molecular weight (>972 Da), and their low octanol/water partition coefficient 
(approx. log Po/w between -3 and 0) (Irie and Uekama, 1997; Matsuda, 1999). β- and γ-CyDs have 
been previously used as food ingredients in chocolate and mayonnaise for emulsification, grape 
drinks, coffee, ginseng extract, soybean lecithin for taste masking, and in instant tea drink for 
preserving flavor (Szente and Szejtli, 2004).  
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 Selection of the form of CyD depends on two factors, its approval status as a food 
ingredient (α and β are not specified and γ – 5mg/Kg) (Marques, 2010), and its formation constant 
(Kf) as listed in Table 5 (Kfoury et al., 2016a). The higher the formation constant better the 
stability, due to the complementarity (of aromatic ring) between the guest molecule and the CyD 
cavity. The recommended drug properties for enhancing the drug-complex stability are high drug 
hydrophobicity (log P>2.5), low drug solubility (typically< 1 mg/mL), low dose (< 100 mg), and 
low CD: drug ratio (< 2:1). CV with drug hydrophobicity of log Po/w = 3.52 and solubility 0.11 g/L 
shows an excellent potential to be included in Cyd complexes (Ben Arfa et al., 2006). 
 The most common stoichiometry of lipophilic molecule such as carvacrol and CyD 
complex reported in the literature is 1:1, meaning one molecule of CV forms a complex with one 
CyD molecule (Loftsson et al., 2005). This is also observed through molecular modeling study 
(Figure 15), where guest CV or thymol penetrate the CyD via their methyl moiety and the isopropyl 
group pointing to the secondary wider rim, to form most stable inclusion complexes (Kfoury et al., 
2016a).  
 The complexation between a guest molecule and CyD molecules occurs in four steps. 
1. Displacement of polar water molecules from the apolar CyD cavity. 2. Formation of hydrogen 
bonds as the displaced water returns to the pool. 3. Reduction of the repulsive interactions between 
the hydrophobic guest molecule and the aqueous environment. 4. Increase in hydrophobic 
interactions as the guest inserts itself into the apolar CyD cavity (Del Valle, 2004).  
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2.9 Tables and Figures 
Table 1. Programs to address undernutrition in India. 
Program Organization Service Beneficiary Reference 
Integrated Child 
Development 
Scheme (ICDS) 
– since 1975 
Government of 
India – 
Anganwadi 
Centers 
Supplementary foods 
Pre-school education 
Health and Nutrition 
Education 
Health Services 
Children 
under age 6 
(34 million) 
Pregnant and 
Lactating 
Mothers (7 
million) 
http://icds-wcd.nic.in/icds/ 
Midday meal 
(MDM) scheme 
in schools – 
since 1995 
 
Government of 
India 
ISKCON Food 
Relief 
Foundation 
Akshaya Patra 
Foundation 
Freshly hot cooked 
plant-based meals – 300 
Cal + 8 to 12 g protein 
School going 
children age 
(6-14) 
(1.3 million) 
http://mdm.nic.in/ 
National Rural 
Health 
Management 
(NRHM) 
Reproductive 
Child Health 
(RCH-II) – since 
2013 
Government of 
India 
Antenatal care, 
counseling, 
micronutrient 
supplementation, 
immunization, postnatal 
care, counseling, 
deworming, health 
checkup 
Pregnant and 
Lactating 
Mothers 
Children (0-6 
years) 
http://nrhm.gov.in/nhm/about-
nhm.html 
Kishori Shakti 
Yojana 
Government of 
India 
Supplementary 
Nutrition, Iron Folic 
Acid supplementation, 
vocational training of 
adolescent girls 
Adolescent 
Girls (11-18 
years) 
http://wcd.nic.in/kishori-
shakti-yojana 
Other programs – Total Sanitation Campaign (Access to sanitation facilities), National Rural Drinking Water 
Program (Access to safe drinking water), Sarva Siksha Abhiyan (knowledge dissemination on nutrition in schools) 
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Table 2. Difference between LNS and RUTF (Dewey and Arimond, 2012). 
LNS RUTF 
Used for prevention (when provided in small quantity) 
or treatment (when provided in large quantity) of 
wasting and stunting which are outcomes of MAM 
Used for treatment of severe acute malnutrition 
Provided in smaller quantities (20-50 g/d) Provided in large quantities (200 – 300 g/d) 
Used for “home-fortification” and to complements the 
foods already consumed by children 
Temporarily replaces most or all other foods besides 
breast milk 
Relatively low cost Relatively high cost 
Example –  
Nutributter – LNS Small Quantity (108 kcal/d for 4 – 6 
weeks) 
Plumpy’Doz – LNS Medium Quantity (247 kcal/d) 
Plumpy’Sup – LNS Large Quantity (75 kcal/kg body 
weight/d for 6 – 8 weeks) 
Example –  
Plumpy’Nut (200 kcal/kg body wt./d for 6 to 8 weeks) 
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Table 3.  Clinical trials on LNS supplementation in children. 
LNS Country Design Subjects 
(number)  
Duration Impact Reference 
LNS 50 and 
LNS 25 g/day 
Malawi Randomized, 
controlled, 
single-blind trial 
6 month 
(n=182) healthy 
rural infants 
12 months Reduction in 
incidence of 
severe stunting 
(JC Phuka et 
al., 2009; 
Phuka et al., 
2008) 
LNS 
(25-75 g/d) 
Malawi Randomized, 
controlled, 
parallel-group, 
investigator-
blind 
6-17 month old 
underweight 
infants 
12 weeks Not conclusive (Kuusipalo et 
al., 2006) 
Ready to use 
LNS 
Niger Blanket 
distribution 
Under 3 
(n=60,000) 
6 month 
distribution 
Reduced severe 
wasting 
(Defourny et 
al., 2009) 
Nutributter Ghana Randomized, 
controlled 
6-12 months 
(n=313) 
12 month Reduced 
prevalence of 
iron deficiency 
and improved 
growth 
(Adu-
Afarwuah et 
al., 2008; 
Adu-
Afarwuah et 
al., 2007) 
Fortified 
Soybean-
maize-
sorghum 
RUCF 
Democratic 
Republic of 
Congo 
Randomized, 
controlled 
6 months 
(n=1383) 
6 months No reduction of 
stunting or 
underweight 
(Bisimwa et 
al., 2012) 
LNS Haiti Randomized, 
controlled 
6-11 months 
(n=589) 
6 months 
intervention 
and 6 
months 
follow-up 
Improved 
linear growth 
of children 
(Iannotti et 
al., 2014) 
Peanut-/soy-
based 
fortified 
spread 
Malawi Randomized, 
Controlled 
6 months 
(n=240) 
18 months Improved 
weight gain 
(Lin et al., 
2008) 
LNS (280 
kcal) 
supplemented 
with corn-soy 
blend 
Malawi Randomized, 
Controlled 
6 months 
(n=240) 
12 months Non-
conclusive 
(Mangani et 
al., 2015) 
Ready to use 
fortified 
spread 
Malawi Randomized 6-18 months 
(n=176) 
12 weeks Not conclusive (J Phuka et 
al., 2009) 
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Table 4. Clinical trials on omega-3 fatty acid fortified LNS supplementation in children 
LNS 
Omega 3 
source 
Country Design Subjects Duration Impact Reference 
High-oleic 
RUTF 
High-oleic 
peanut, palm 
oil, and 
linseed oil 
Malawi Prospective
, 
randomized
, double-
blind 
141 children 
with SAM 
(6-59 
months) 
4 weeks Improved DHA 
and EPA levels 
in plasma 
(Hsieh et al., 
2015) 
RUTF Flaxseed oil 
and Fish oil 
Kenya Randomize
d controlled 
trial 
60 children 
(6-50 
months) 
3 months Fish oil  RUTF 
increased n-3 
PUFA status 
whereas 
Flaxseed oil had 
no effect on 
DHA  
(Jones et al., 
2015) 
 
 
 
Table 5. Characteristics of α-, β- and γ- Cyclodextrins 
Characteristics α – β – γ – 
No. of glucose units 6 7 8 
Cavity diameter (nm) 0.47 0.60 0.75 
Height of torus (nm) 0.79 0.79 0.79 
Approval status as food ingredient NS NS 5 mg/kg 
Formation constant with carvacrol (Kf) M-1 454 2620 999 
Formation constant with thymol (Kf) M-1 107 1467 233 
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Figure 2. Forms of undernutrition (Black et al, 2008). 
 
 
 
 
 
 
 
 
Figure 3. Waterlow’s classification of the degree of undernutrition (Waterlow et al., 1977). 
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Figure 4. Weight for age distribution curve for children (<3 years) in India compared to global 
reference population (Taken from Bhutia, 2014). 
 
Figure 5. A conceptual model of effects of undernutrition throughout the life cycle (Adapted 
from ACC/SCN, 2000). 
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Figure 6. UNICEF conceptual framework of relations between basic, underlying and immediate 
causes to maternal and child undernutrition and its short-term and long-term consequences (Black 
et al. 2008). 
 
Figure 7. Infection-undernutrition vicious cycle (Katona and Katona-Apte, 2008) 
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Figure 8. Undernutrition and parasitic infection interaction (Cunnigham-Rundles, 2008) 
 
Figure 9. Intestinal parasites (left to right), protozoans; Cryptosporidium parvum and Giardia 
lambia, and helminths; Ascaris lumbricoides (roundworm) and Ancylostoma duodenale 
(hookworm). 
 
 
 
Figure 10. Anganwadi centers in India, hot cooked rice and pulse meal, kitchen setting to cook 
those meals and take-home rations (left to right). 
 
 
 
 
 
Figure 11. Examples of currently available small, medium and large quantity LNS (Source: 
http://www.nutriset.fr/en/homepage-nutriset.html). 
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Figure 12. Life cycle of Cryptosporidium parvum (Adapted from Center for Disease Control and 
Prevention http://www.cdc.gov/parasites/crypto/biology.html). 
 
Figure 13. Chemical structure of carvacrol (left) and thymol (right). 
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Figure 14. Structures of α-, β- and γ- Cyclodextrins 
 
 
Figure 15. Molecular complex of β-CyD-CV and β-CyD-thymol (Taken from Kfoury et al., 2016) 
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Chapter 3: Omega-3 Fortified Lipid-based Nutrient Supplement – Development, 
Characterization and Consumer Acceptability1  
 
3.1 Abstract 
Background: Lipid-based nutrient supplements (LNS) with balanced omega-6/omega-3 fatty acid 
ratio are beneficial for undernourished children. Incorporating omega-3 PUFA sources to LNS 
formulations is challenging due to storability, oxidative stability, and off-flavor issues resulting in 
reduced shelf-life and poor consumer acceptability 
Objective: To systematically develop an omega-3 fortified LNS formulation, using flaxseed oil, 
by optimizing process variables based on stability parameters, characterizing the physicochemical 
properties, and evaluating consumer acceptability.  
Methods: LNS formulations were designed to yield approximately 452 kcal, 13.2 g of protein, 30 
g of fat, and 53 g of carbohydrates. Response surface methodology (RSM) with four-factor-three-
level: omega-3 fatty acid source (flaxseed oil) (0-10%), antioxidant (ascorbyl palmitate: 0.0-
0.03%), emulsifier (soy lecithin: 0.5-1.5%), and storage time (0-6 months) was employed to 
optimize LNS’s functionality and storage stability. Factor effects were evaluated for peroxide 
value, oil separation, water activity, moisture content, hardness, and vitamin C content of samples. 
Consumer acceptability was assessed using a nine-point hedonic scale.  
                                                          
1 Reprinted, with permission, from: Gaur, S., Sloffer, E. M., Ojha, A., Patra, F., … Andrade, J. E. 
(2017). Omega-3-Fortified Lipid-Based Nutrient Supplement. Food and Nutrition Bulletin, 
037957211770123. 
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Results: Flaxseed oil (FO) was the most significant factor (p<0.05) in reducing storage stability 
in terms of peroxide value (0 to 7.75 mEq/kg fat) after six months. Reduction in vitamin C (10%) 
and water activity whereas an increase in lipid separation were observed after six months. Optimal 
levels to maximize storage time and FO, and minimize oxidation were 0.02% antioxidant, 1.5% 
emulsifier, and 4.9% FO. 5% FO addition resulted in omega-6/ omega-3 (LA/ALA) fatty acid ratio 
to 2.6. Indian women and students accepted LNS formulations with or without FO similar to other 
commercial supplements.  
Conclusions: An LNS with reduced omega-6/omega-3 PUFA ratio was successfully formulated 
and optimized for ingredients and stability using RSM, which resulted in recommendations for 
specific amounts of antioxidant, emulsifier, and FO to obtain an increased storage time with lower 
oxidation. A 20-g serving size of this formula provides 90 kcals and can contribute a significant 
quota of micronutrients and essential fatty acids to children with moderate acute malnutrition.  
43 
 
3.2 Introduction 
Moderate acute malnutrition (MAM) afflicts 33 million children worldwide, of which 20 
million children live in India alone (WHO, 2013). MAM is characterized by weight for height 
score between -3 and -2 Z-scores compared with a reference population, or by Mid-Upper Arm 
Circumference (MUAC) < 12.5 cm (WHO, 1999). Supplementary feeding programs are widely 
used to tackle MAM and avoid mortality by reducing deterioration into severe acute malnutrition 
(SAM), despite insufficient evidence on their effectiveness (Annan, Webb, & Brown, 2014). In 
India, MAM is addressed through take-home rations such as mixed flours (sattu), sweets (sheera), 
and porridge (upma), or sometimes raw ingredients such as rice and pulses. Although such 
interventions have been useful in improving some health outcomes, there are still issues with 
nutritional adequacy and consumption compliance due to the low acceptability of products, and 
additional food preparation requirements (Varma et al., 2007; Bhagwat et al., 2014).  
Lipid-based nutrient supplements (LNS) are ready to use energy and nutrient dense food 
products that are suitable to complement most food rations, especially due to their longer shelf life 
and convenience. Existing LNS have been widely successful in treating SAM among at-risk 
children and has instigated the development of similar or improved alternative foods for addressing 
MAM to overcome the issues with existing supplementary feeding program (Dewey & Arimond, 
2012).  
In the past two years, there has been an increased interest in improving the omega-3 fatty 
acid profile of conventionally used peanut based formulations, which are rich in omega-6 linoleic 
acid (LA) but contain negligible omega-3 alpha linolenic acids (ALA) (Brenna et al., 2015; Hsieh 
et al., 2015; Jones et al., 2015). Balanced Omega-6/Omega-3 polyunsaturated fatty acids (PUFA) 
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are beneficial for children suffering from SAM or MAM, as omega-3 ALA serve as precursors for 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which play a significant role in 
modulation of tissue inflammation, immune function, and overall neural development (Calder, 
2006). In addition, omega-3 PUFA modulates intestinal inflammation, common in malnourished 
children, that results in malabsorption of nutrients from the diet (Gupta et al., 2011; Teitelbaum & 
Allan Walker, 2001). Currently, there are no specifications for omega-6/omega-3 PUFA ratio in 
LNS, however, the importance of balanced PUFAs in LNS is now well recognized (Brenna et al., 
2015).  
Incorporating omega-3 PUFA sources to LNS formulation is challenging due to storability, 
oxidative stability, and off-flavor issues resulting in reduced shelf-life and poor consumer 
acceptability (Ganesan, Brothersen, & McMahon, 2014). The aim of this study was to 
systematically develop an omega-3 fortified LNS formulation using flaxseed oil by optimizing 
process variables based on stability parameters, characterize its physicochemical properties, and 
evaluate its consumer acceptance. This process will result in a stable and acceptable 
complementary spread that is highly palatable, cost-effective, locally produced and that provides 
required micronutrients, which could be included in the daily meals of children at schools or 
supplementary feeding centers in India.  
 
3.3 Materials and Methods 
 Ingredients. Ingredients included chickpea flour (Spicy World, Houston, TX), soy flour 
(Bob’s Red Mill, Milwaukee, OR), maltodextrin (Honeyville, Inc, Brigham City, UT), FO 
(Spectrum Naturals, Inc, Melville, New York), clarified butter (ghee; AMUL, Anand, India), skim 
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milk powder (Barry Farm, Cridersville, OH), soybean oil (Crisco, Orville, OH), coconut oil 
(Spectrum Naturals, Inc, Melville, New York), palm oil shortening (Crisco, Orville, OH), vitamin 
mineral mix (Watson Inc, West Haven, CT), soy lecithin (Now, Bloomingdale, IL), antioxidant 
ascorbyl palmitate (Spectrum Chemical, Gardena, CA), and cocoa powder (Hershey’s, Hershey, 
PA). LNS A20 was donated by USAID, and Sattu Maavu was procured from a commercial 
supplier in India. Three-layer minipouches (PAKVF4) were purchased from IMPAK Corporation 
(Los Angeles, CA).  
 Chemicals. Hexane, acetic acid, potassium iodide, sodium thiosulphate, starch solution 
and sand were procured from Fisher Scientific. Chloroform, metaphosphoric acid, 
ethylenediaminetetraacetic acid, sodium phosphate monobasic and L-ascorbic acid were 
purchased from Sigma-Aldrich (St. Louis, MO).  
 Recipe formulation. Recipes for LNS were designed using ESHA Food Processor Diet 
Analysis and Fitness Software (ESHA Research v. 10.10.0) and the Indian nutrient database 
(Gopalan et al., 1989) to yield approximately 13% protein (i.e. dairy, chickpea, soy), 40% 
carbohydrate (i.e. sucrose, maltodextrin), 38% fat (different blends of ghee, soybean oil, coconut 
oil and flaxseed oil), and 3% complete vitamin and mineral mix (Table 6). FO was incorporated at 
5% and 10% level by replacing soybean oil to prevent any textural changes, as they have a similar 
viscosity (800 mPa.s) and specific gravity (0.91 at 25 oC) (El-Waseif et al., 2013). Formulations 
were designed to meet the World Food Program (WFP) LNS technical specifications (Nguyen & 
Bouzambou, 2014) and specifications described by Chaparro and Dewey (2010). Ready to use 
therapeutic food (RUTF) specifications were obtained from MSF/UNICEF (Caron, 2012) and 
Commercial Item Description (2012) for standards not listed, but specified by Nguyen & 
Bouzambou (2014).  
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 General LNS preparation. Figure 16 illustrates the preparation of LNS. Weighed 
flours were toasted at 110 °C for 120 min in a forced convection hot air oven (Mechanical Oven; 
Precision Scientific, Fisher Scientific, Marietta, OH). Flours were added to other dry ingredients 
and mixed (2 min); this constituted the dry mix. Variations in the content of antioxidant and 
emulsifier were made at this point. The dry mix was added to a wet grinder (PG503, Premier 
Wonder), and contents were mixed (3 min) to ensure homogenous mixing and size reduction. The 
fats and oils were brought to room temperature (23±2 °C) and mixed in a glass bowl for 2 min. 
Variations in the amount of flaxseed oil were made at this point. The lipid mixture was added to 
dry contents in a wet grinder and blended for 5 min.  
 Packaging and storage. The product was filled into 3-layer minipouches and heat-
sealed under nitrogen (99.99% pure) using a Minipack America Sealer (MVS 31 – XP) with the 
following settings vacuum 50%, gas ratio 20% and time 2.5 s. Sealed pouches were held at 40±2 
°C for 6 months for accelerated shelf life testing equivalent to 12 months at room temperature (~30 
°C). 
 Water activity. Sample water activity was measured using an Aqualab water activity 
meter (AOAC, 1980). Sample (1 g) was weighed into 15 mL disposable sample cups and inserted 
into the instrument (Aqualab 4TE, Decagon Devices Inc., USA). 
 Peroxide value. Peroxide value of samples was measured in triplicate using a modified 
method from AOCS (2004), as described by Crowe & White (2001).  
 Moisture content. Modified oven drying method (sand pan technique) was used for the 
estimation of moisture content (Bradley et al., 2010). Aluminum metal dishes with lids containing 
10 g of sand were dried along with a glass rod for 1 h. The dish was weighed to the nearest 0.0001 
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g after cooling in a desiccator. Sample (5 g) was added to the dish and thoroughly mixed with sand 
using the glass rod. Samples were dried in a hot air oven for 5 h at 95°C.  
 Lipid separation. Lipid separation was measured in triplicate using a modified method 
of Hinds et al., (1994) and Perlman (1999). Pouches were thoroughly and uniformly massaged for 
2 min before opening. A 30 g sample was carefully transferred to a 50 mL centrifuge tube. To 
simulate natural separation, tubes were centrifuged at a low-speed (300 ×g) at 22°C (Sorvall ST 
16R with TX400 swinging bucket rotor, Thermo Sci.) for 3 min. A digital Vernier caliper was 
used to determine the height of lipid layer separated at the top of the sample.  
Texture analysis. Sample hardness was measured using a texture analyzer (TA-XT2; 
Texture Technologies Corp., Scarsdale, NY) following a method adapted from Ahmed & Ali 
(1986). Pouches extracted from incubator were uniformly massaged for 2 min and 50 g sample 
was placed in Petri dishes (15 cm  by 1.5 cm height) in triplicates. Samples were left undisturbed 
for 1 h and temperature was monitored using an infrared thermometer. During analysis, each 
sample dish was secured to the base. The probe (50 mm diameter, flat surface) was moved at a 
crosshead speed of 0.5 mm/s with 4 mm penetration. Hardness was measured as the peak force 
(N) of the first compression cycle.  
Vitamin C determination. The method of Tarrago-Trani et al., (2012) with modifications 
was used for extraction and measurement of vitamin C. The sample size used was 0.2 g and the 
extraction buffer was 1 mM EDTA/4% meta-phosphoric acid. Separation and quantification of 
vitamin C were carried out by reverse phase separation and UV detection (PDA at 265 nm) using 
a Waters HPLC with an isocratic pump system. An ISIS C-18 column (150 × 4.6 mm, 3 μm particle 
size; Supelco-Sigma, St. Louis, MO) was equilibrated with a mobile phase consisting of 25 mM 
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sodium phosphate buffer, pH 3.0 and pumped at 0.4 mL/min. Vitamin C was quantified using 
HPLC grade external standards. Results were expressed as mg of vitamin C per g samples. 
Microbiological analysis. Microbial analysis was conducted for samples (25 g) at 0 and 6 
months for total viable count (ISO 4833-1:2013) and Salmonella (ISO 6579). Coagulase test was 
done for S. aureus in 10 g sample. 
Response surface methodology for formula optimization. RSM, which includes the 
design of experiments, selection of levels of variables, fitting mathematical models, and 
optimization of variables, was applied in this study (Nwabueze, 2010). Face-centred central 
composite design for four independent variables (i.e. antioxidant, emulsifier, storage time, and FO 
content) at three levels was used for the experimental plan, resulting in 30 combined experiments. 
Responses associated with moisture content, water activity, peroxide value, lipid separation, 
hardness, and vitamin C content were recorded. For each response, its relationship with another 
variable was determined by fitting data to the second-order reaction using Equation 1.   
Y=β
0
+∑ β
i
Xi+∑ βijXi
2+4i=1 ∑ ∑ βjXiXj+εji
4
i=1       
 Equation 1 
Where Y is the predicted response; β0 is a constant; βi is the linear coefficient; βij is the quadratic 
coefficient βij is the interaction coefficient of variables i and j; and Xi and Xj are the independent 
variables. 
The statistical adequacy of the model was tested using the Fisher test value (F-ratio), the 
coefficient of determination (R2), and Lack of Fit (LOF) test. To visualize the relationship between 
the response and the experimental levels for each factor and to deduce the optimum conditions, 
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2D and 3D response surface plots were generated. Table 7 shows the respective low and high 
levels for the factors coded. 
Consumer acceptability. Research protocols using human subjects were approved by the 
Institutional Review Board at the University of Illinois, Urbana–Champaign (UIUC). The study 
was conducted in collaboration with the Mansinhbhai Institute of Dairy and Food Technology 
(MIDFT), Mehsana, India. Participants rated the characteristics of samples presented on a 9-point 
hedonic scale (ISO 11136:2014) from dislike extremely to like extremely. Further, participants 
ranked the samples from 1 to 4, where 1 was the top-ranked sample. Eighty-six students (18-24 y) 
and twenty-five women (18-45 y) with young children (1-6 years) at home, otherwise healthy (no 
diarrhea, cold or fever) were randomly recruited from MIDFT and within a 20-km radius from 
MIDFT, respectively. Written consents were obtained from subjects. All the documents presented 
to women were translated into the local language (Gujarati). The participants were trained and 
instructed in local language by the team. Samples evaluated were: LNS without flaxseed oil (LNS 
w/o FO), LNS with flaxseed oil (10% FO; LNS w FO), LNS A-20 and Sattu Maavu (a 
commercially available nutrition supplement in India). The responses from students were recorded 
on a visual analog scale using Qualtrics online (Online Survey Software & Insight Platform) and 
from women on paper-based forms. For students, the products were evaluated based on taste, color, 
sweetness, smell, stickiness, texture, appearance and overall acceptability; whereas for women, 
the characteristics were taste, color, smell, mouthfeel, appearance and overall acceptability. 
LNS samples were prepared based on ingredients shown in Table 6. LNS w FO was 
prepared by replacing soybean oil with FO at a level of 10% of the final weight. LNS-A20 was 
prepared based on the recipe developed by Briggs et al., (2007) using: maltodextrin, soybean oil, 
confectionary sugar, non-fat milk powder, whey protein concentrate, cream powder, lecithin, pea 
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protein isolate, vitamin/ mineral premix, salt, and antioxidants. Sattu Maavu was obtained locally 
and contains millet (finger and pearl), corn, wheat, barley, mung bean, groundnut, cashews, sago, 
and cardamom. Samples were prepared in one-kg batches at the Food and Dairy Technology Lab 
at MIDFT. Coded samples (2±0.5 g) maintained at 25±2°C were presented at random to the 
participants in clear disposable sensory cups under well-lit conditions. Water (~25±2°C) and 
crackers were provided for rinsing between samples. All testing sessions were scheduled between 
11:00 AM and 1:00 PM. 
Statistical Analyses. Design Expert v7.0 was used for experimental design, generation of 
RSM plots and optimization. The variables were analyzed using the General Linear Model (GLM) 
procedure, and means were compared using Tukey’s Studentized Range Test and considered 
statistically different at p ≤ 0.05. A Full Factorial Completely Randomized Design was used to 
study the effect of independent variables using GLM procedure. The normality assumption was 
tested by the Shapiro–Wilk test. Data from consumer acceptability test with women were analyzed 
with Kruskal-Wallis test using npar1way function in SAS and the Dunn’s test for post hoc mean 
analyzes. All statistical analyses were performed using SAS 9.4. The Friedman rank sum test was 
performed to classify samples based on ratings (O’Mahony, 1986). The results are presented as 
means ± SD. 
 
3.4 Results 
Development of LNS product. Each 100 g of LNS provided 452 kcal, 13.2 g of protein, 
30 g of fat, and 53 g of carbohydrates. Flaxseed oil incorporation at 5% and 10% level reduced the 
omega-6/ omega-3 (LA/ALA) fatty acid ratio to 2.6 and 1.4 compared to 5.8 in control LNS with 
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0% FO (Table 8). All formulas of the LNS showed a higher proportion of saturated fatty acids and 
a lower omega-6/omega-3 ratio than the LNS-A20 counterpart (Table 8). 
Responses to RSM. Results for the following response variables: water activity, lipid 
separation, peroxide value, hardness, moisture content, and vitamin C are presented in Table 9. 
The estimated regression coefficients of the fitted model are given in Table 10. ANOVA indicated 
that responses Y2, Y3, Y4, and Y6 were significant at p ≤ 0.001, and model Y1 was significant at p 
≤ 0.05. Also, all the coefficients of determination (R2) were greater than 0.73, except for moisture. 
Thus, more than 73% of the total variations provoked by the experimental conditions could be 
explained by the models fitted to the regression curve.   
Only significant terms in second order polynomials were used to generate three-
dimensional RSM plots and two-dimensional line plots. Peroxide values ranged from 0 to 7.75 
mEq/kg fat and no oxidation was determined in samples at 0 and 3 months (Figure 17A). Slight 
oxidation was detected in the samples containing 5 and 10% FO at 6 months. Storage time and FO 
content had a significant factor and interaction effect. Lipid separation ranged from 0 to 2.27 mm 
and was affected by storage time and emulsifier content (Figure 17B). An interaction was observed 
between lipid separation and these two variables. Fresh samples did not show oil separation. Water 
activity decreased in samples from 0 to 3 months (Figure 18A). No further changes in water 
activity were observed after 3 months. Moisture content remained the same throughout the study, 
ranging from 0.0476 to 0.1657 % (Figure 18B). Only storage time had an effect on hardness (N), 
in which the force (ranging from 10.93 to 45.31 N) required to penetrate the samples decreased 
during storage (Figure 18C). Vitamin C content declined in samples from 0 to 3 months in storage, 
but it remained the same after 3 months (Figure 18D). 
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Conditions for optimum response. For optimization, multiple regression equations were 
solved to maximize FO content, storage time, and minimize oxidation, using a multiple response 
method called desirability. The solution to obtain a storability of 3.61 months was a product of 
mixing ingredients containing 0.02% antioxidant, 1.49% soy lecithin, and 4.87% FO.  
Microbiological testing. At 0 and 6 months, the total viable count of samples was 100 ± 
25 CFU/g against the tolerance of 10,000 CFU/g. LNS samples were negative for Salmonella and 
S. aureus (coagulase test).   
Consumer acceptability. Demographic results showed that a large proportion (72%) of 
the women was involved in farming and cattle rearing businesses. Almost all women (92%) 
provided unfortified homemade complementary foods to their children, which mostly consisted of 
grains, pulses, fats, and, in some occasions, fruits.  
Consumer acceptability ratings from both subject groups and for all LNS samples were 
above 6.0 (“like slightly”) on the 9-point hedonic scale. Only Saatu Maavu received acceptability 
ratings below 6.0. Results from acceptability tests can be found in the Supplementary materials, 
Figures 19a and 19b. Among sensory attributes, clear differences in acceptability ratings were 
observed for taste, mouthfeel, and appearance. For most sensory attributes, LNS samples were 
accepted above Sattu Maavu. Subjects accepted LNS w FO to a lesser extent in terms of taste and 
smell than the other LNS samples. Both women and students consistently ranked LNS w/o FO and 
LNS-A20 as number one and two (data not shown) compared to the other products. Sattu Maavu 
was consistently ranked last (p ≤ 0.05). 
3.5 Discussion 
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An omega-3 fortified LNS product was designed using staple ingredients and optimized 
using RSM with the objective to improve omega-3/omega-6 PUFA balance and to serve as a take 
home ration or complement the meals provided at supplementary feeding centers (Anganwadi) in 
India. A 20-g serving size of this formula provides 90 kcals and can contribute a significant quota 
of micronutrients and essential fatty acids to children with MAM. Flaxseed oil (FO), a vegetarian 
source of omega-3 PUFA, was selected for its high content of ALA, the precursor of long chain 
omega-3 EPA and DHA, and for its additional benefits beyond energy, such as anti-inflammatory, 
antithrombotic and hypolipidemic effects (Takahata et al., 1998). Other ingredients such as 
chickpea flour, milk powder, soybean oil, ghee, and coconut oil were selected due to their 
commercial availability, cost, and acceptability. The obtained lipid blend is high in saturated and 
medium chain fatty acids, which increases oxidative stability. Ascorbyl palmitate was the 
antioxidant of choice based on the recommendations from Nguyen & Bouzambou (2014). Finally, 
cocoa powder was used to improve flavor and aesthetic appeal.  
Enteric infection, a trigger for inflammatory response and intestinal inflammation, is very 
common among malnourished children in India, resulting in nutrient malabsorption (Gupta et al., 
2011). The omega-6/omega-3 ratio is an indicator for the balanced synthesis of eicosanoids in the 
body and a lower ratio is recommended for undernourished children not only for normal growth, 
cell functioning, and immune function but also for an adequate anti-inflammatory response (Gogus 
& Smith 2010; Brenna et al., 2015; Calder, 2006). In a recent study of children with SAM, a two-
month supplementation with RUTF high in oleic acid and with a 1:1 LA:ALA ratio increased 
circulating EPA and DHA and reduced arachidonic acid compared to standard RUTF with 
LA/ALA ratio of 53:1 (Hsieh et al., 2015). In another study, a peanut-based RUTF fortified with 
FO significantly increased plasma EPA and docosapentaenoic acid, but not DHA among children 
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suffering from SAM (Jones et al., 2015). A four-week treatment with FO (14 g/day) decreased the 
levels of pro-inflammatory cytokines among adult subjects (Caughey et al., 1996). In contrast, a 
lower dose (i.e. 2 or 3.5 g/day) did not have this effect (Thies et al., 2001; Wallace et al., 2003).  
Most companies struggle with the addition of PUFAs into product formulation. Any 
encapsulation of PUFAs will impact product cost. In addition, plant sources of PUFAs are more 
suitable for the Indian culture. Although an optimal ratio is important in inflammation, it cannot 
be at the expense of product’s flavor and acceptance. The most difficult problems in formulation 
with PUFAS are oxidation within storage and the resultant flavors. In this study, we found that 
reducing the FO content in LNS to 5% will balance the essential fatty acid ratio, while enhancing 
its stability during storage and consumer acceptability. 
RSM studies pinpointed adequate levels of FO, antioxidant, and lecithin that resulted in 
lower oxidation during storage. Studies also helped identify factor effects and their interactions 
and to minimize experimental runs and time. A similar optimization technique was used to evaluate 
physicochemical and sensory properties of peanut pastes (Muego-Gnanasekharan & Resurreccion, 
1992). The main changes associated with accelerated storage were increased oxidation (i.e. 
peroxide value), decreased water activity, decreased product hardness, increased separation of fat 
and oil from the matrix, and increased vitamin C degradation. 
Higher peroxide values in LNS were associated with increased addition of FO (at a level 
of 10%). Essential fatty acids in FO are less stable and more susceptible to electrophilic attack and 
metal-catalysed autoxidation (Gunstone, 1996). Briggs et al., (2007) found a similar trend in LNS-
A20 samples containing a higher proportion of unsaturated oils. Higher peroxide values were 
reported in FO-containing cookies (>30%) compared to controls stored at 45 °C for 28 days 
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(Rangrej et al., 2015). Both storage time and temperature influenced sample oxidation similar to 
the observations of Riveros et al., (2010) from studies with peanut pastes and Sumainah et al., 
(2000) from studies with peanut-sesame soy blends. Although the peroxide values of LNS were 
higher after 3 months, these values remained well below the permitted level of 10 mEq/kg oil, a 
threshold for perception of rancid flavors in oils (FAO/WHO, 1999).  
Water activity (Aw) of LNS products is often low, which enhances their ability to last long 
in harsh storage conditions. A decrease in Aw from 0 to 3 months could be a result of moisture 
equilibration in the samples, in which free water migrated from ingredients with high to low Aw, 
such as from toasted flours and sugar, thus reducing the vapor pressure (Guillard et al., 2003). The 
Aw remained below 0.6 after 3 months, which prevented the growth of microorganisms, as 
confirmed by microbial analysis, and resulted in a product safe for consumption at all time points. 
Despite the changes in Aw, the moisture content remained unchanged. This could be attributed to 
the packaging material, which prevented migration of moisture from the external environment. 
Briggs et al., (2007) reported similar moisture results in LNS-A20 samples during a six-month 
accelerated storage.   
Often the oil ingredients in LNS tend to separate after several months in storage. Decreased 
hardness during high-temperature storage could be attributed to melting of fat crystals and oil 
penetration in the matrix during the quiescent conditions. Similar results were observed by Muego-
Gnanasekharan & Resurreccion (1992), in which hardness of peanut paste samples stored at 40 °C 
decreased by 43% after 12 months. These authors also reported a higher separation of fat and oil 
from the product matrix; an indication of lower product quality and that could result in higher 
oxidation rates. Lecithin content, storage time and their interaction had an effect on oil separation. 
Oil separation increased with time because melted lipid crystals and lecithin rose to the surface 
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after the collapse of the lipid crystal network at a high temperature. Furthermore, differences in 
lipids’ specific gravity resulted in flocculation, then partial or complete coalescence with time 
(Radocaj et al., 2011; Walstra, 2002). UNICEF recommends minimal oil separation (Caron, 2012); 
however it does not provide any indication as to how to measure separation or quality 
specifications.  
Vitamin C reduction during storage might be attributed to autoxidation at high temperature 
and in the presence of metal catalysts such as iron and copper. Similar reductions were observed 
in peanut paste stored at 40 °C for 3 months (Yeh et al., 2002). After 3 months, vitamin C levels 
remained unchanged probably due to the lower Aw as reported previously (Yeh et al., 2002). In 
another study, vitamin C losses (~20%) were reported in LNS-A20 after 6 months of storage at 
38°C (Briggs et al., 2007). Therefore, overage amounts will be needed to ensure vitamin C is 
present by the end of the shelf life of products. 
Although most times overlooked in emergency relief products for supplementation in low-
income settings, consumer acceptability tests are important to evaluate the likelihood of product 
adoption by end users and to address potential organoleptic issues based on subject’s feedback. 
Women were chosen instead of infants for this study as they often taste the food before feeding it 
to their children, and their acceptability of a product is positively associated with both their 
children acceptability and the likelihood to use the product for such purposes (Skinner et al., 2002). 
Students were selected to determine acceptability among general consumers. Although most 
products evaluated scored above average on several attributes (i.e. values ≥ 5), the LNS w/o FO 
was the most acceptable among women and students. FO’s taste was the primary reason for low 
acceptance. Low consumer acceptability was reported by a semi-trained sensory panel who 
evaluated cookies containing FO at a level of 40% or higher as a direct replacement for shortening 
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(Rangrej et al., 2015). Similarly, a lower acceptability in terms of crust color, flavor, mouthfeel, 
and overall acceptability was reported in bagels with increased FO content (Alpaslan & Hayta, 
2006). FO’s PUFAs oxidize readily, which leads to the accumulation of undesirable flavors (Goh 
et al., 2006). The brown color of the LNS was appealing among subjects. Chocolate-based 
products are available in India and thus participants could relate to the LNS products in terms of 
color, taste, and flavor. In Bangladesh, a study found that 60% of the women did not accept the 
taste of peanut-based LNS (Ali et al., 2013), which led to reduced acceptance. Therefore, 
appropriate use of flavors in LNS products is critical for their successful adoption among end users.  
Some of the potential limitations of this study may need to be addressed prior to the full 
adoption of this and similar LNS products. First, the activation energy to predict shelf life was not 
determined due to lack of at least one additional temperature point (Sewald & DeVries, 2013). 
Second, the sample size for acceptability tests was small and did not include children or adult men. 
This reduces the extrapolation of results. Due to  significant ethnic diversity in India, it is important 
that sensory tests be conducted with similar formulations before production and delivery of 
products to other states and regions.   
 
3.6 Conclusions 
An LNS with reduced omega-6/omega-3 PUFA ratio was successfully formulated and 
optimized for ingredients and stability using RSM; this resulted in recommendations for specific 
amounts of antioxidant, emulsifier, and FO to obtain an increased storage time with lower 
oxidation. Flaxseed oil addition was the most significant factor in reducing storage stability. Due 
to vitamin C reduction during the first three months, adjustments in the micronutrient mix are 
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needed (i.e. overage). LNS with higher FO content (10%) had lower acceptability than both LNS 
w/o FO and LNS-A20, which may be attributed to its characteristic off-flavour. Based on the 
importance of essential fatty acids in growth and development and their role in inflammation, the 
next generation of LNS products should aim at maximizing the amount of omega-3 fatty acids and 
their stability in storage and ultimate consumption compliance, while minimizing their oxidation.   
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3.7 Tables and Figures 
  
Table 6. Recipe formulation for LNS 
Ingredient Quantity (g) 
Soybean Oil 10 
Coconut Oil 8 
Ghee 8 
Soy lecithin Emulsifier 1 
Shortening (Palm oil) 4 
Chickpea flour (Toasted) 17 
Soy flour, full fat (Toasted) 10 
Non-Fat/ Skimmed Milk Powder    15.25 
Sugar 10 
Flaxseed oil* 5 
Vitamin-Mineral Mix 3.75 
Cocoa Powder 2 
Maltodextrin M100 6 
Total 100 
Vitamin mix (for 100 g LNS)- Sodium (sodium 
chloride) – 100 mg, Potassium (dipotassium 
phosphate) – 800 mg, Phosphorus (dicalcium 
phosphate, dipotassium phosphate) – 350 mg, 
Calcium (dicalcium phosphate, calcium carbonate) 
– 420 mg, Magnesium (magnesium oxide) – 30mg, 
Iron (ferrous fumarate) – 10 mg, Zinc (zinc oxide) – 
10 mg, Copper (cupric oxide) - 1.2 mg, Iodine 
(potassium iodide) – 100 µg, Vitamin A (vitamin a 
palmitate) – 3163.5 IU, Vitamin D3 
(cholecalciferol) – 800 IU, Vitamin E (d,l-alpha 
tocopheryl acetate) – 22.350 IU, Vitamin K 
(phytonadione) – 20.00 µg, Vitamin C (ascorbic 
acid) – 45 mg, Thiamin (Thiamin Mononitrate) – 
0.2 mg, Riboflavin – 2 mg, Niacin (niacinamide) – 
0.5 mg, Pyridoxine (pyridoxine hydrochloride) – 1 
mg, Folic acid – 0.2 mg, Vitamin B12 
(cyanocobalamin) – 2 µg, Biotin – 0.08 mg, 
Pantothenic acid – 3 mg, Selenium (sodium 
selenite) – 30ug. 
*Formula to prepare LNS with 5% flaxseed oil. This 
oil replaced soybean oil in formulation. 
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Table 7. RSM factor variables and levels 
Variables Coded Xi 
Coded levels 
ΔX 
-1 0 1 
Antioxidant: L-ascorbyl 
palmitate (% of sample) 
X1 0.00 0.01 0.03 0.02 
Emulsifier: Soy lecithin 
(% of sample) 
X2 0.5 1 1.5 0.5 
Storage time (months) X3 0 3 6 3 
Flaxseed oil (g) X4 0 5 10 5 
Table 8. Fatty acid profiles (Area %) of various LNS products 
    LNS  
A-20 
Fatty acid  0% FO 5% FO 10% FO  
Octanoic acid 8:0 3.2 3.3 3.4  0.4 
Decanoic acid 10:0 2.6 2.8 2.8  0.8 
Lauric acid 12:0 14.1 15.8 16.0  0.8 
Myristic acid 14:0 6.7 7.1 7.2  2.1 
Myristoleic acid 14:1 0.1 0.1 0.1  0.2 
Palmitic 16:0 17.3 16.3 16.0  17.4 
Margaric (IS) 17:0 5.4 4.2 3.9  4.5 
Stearic 18:0 0.0 0.0 0.0  5.5 
Oleic trans 18:1t 6.0 5.7 5.4  0.0 
Oleic acid 18:1 16.0 16.0 16.1  18.9 
Linoleic acid 18:2 24.0 20.5 17.0  42.9 
GLA 18:3n6 0.3 0.2 0.2  0.4 
ALA 18:3n3 4.1 8.0 11.8  5.7 
LA: ALA ratio  5.8 2.6 1.4  7.5 
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Table 9. Results of face-centered central composite design for optimization. 
Run 
Variables  Responses 
X1 X2 X3 X4  Y1 Y2 Y3 Y4 Y5 Y6 
1 0 0 1 0  0.187 2.090 0.000 10.993 0.087 43.240 
2 1 -1 1 1  0.212 2.190 6.869 15.749 0.085 37.560 
3 -1 -1 -1 -1  0.226 0.000 0.000 31.803 0.119 49.420 
4 1 1 1 1  0.232 1.140 5.941 26.125 0.136 40.120 
5 -1 0 0 0  0.179 0.860 0.000 28.145 0.103 43.210 
6 1 -1 -1 -1  0.223 0.000 0.000 38.893 0.100 47.630 
7 1 -1 1 -1  0.221 2.150 0.000 15.259 0.088 42.150 
8 0 0 0 0  0.198 1.220 0.000 29.537 0.052 41.600 
9 -1 1 1 -1  0.195 1.910 0.000 22.869 0.147 43.770 
10 -1 -1 -1 1  0.227 0.000 0.000 40.129 0.108 49.440 
11 0 0 0 0  0.198 1.530 0.000 28.370 0.106 42.250 
12 0 0 0 0  0.199 1.230 0.000 30.410 0.102 39.020 
13 0 0 -1 0  0.235 0.000 0.000 34.872 0.089 47.210 
14 -1 -1 1 -1  0.184 2.270 0.000 20.996 0.166 40.780 
15 -1 1 -1 1  0.232 0.000 0.000 45.316 0.102 46.340 
16 -1 -1 1 1  0.206 2.040 7.750 23.065 0.048 39.280 
17 0 1 0 0  0.194 0.970 0.000 24.644 0.061 37.670 
18 1 1 1 -1  0.189 1.110 0.000 24.193 0.099 38.400 
19 0 0 0 0  0.230 1.200 0.000 29.430 0.109 41.030 
20 0 0 0 1  0.212 1.520 0.000 31.656 0.100 42.880 
21 0 0 0 0  0.189 2.170 0.000 26.468 0.097 39.430 
22 0 0 0 0  0.194 0.990 0.000 30.606 0.090 43.600 
23 1 1 -1 1  0.226 0.000 0.000 31.332 0.110 46.310 
24 1 -1 -1 1  0.224 0.000 0.000 38.530 0.120 47.210 
25 -1 1 -1 -1  0.238 0.000 0.000 31.705 0.160 41.980 
26 1 1 -1 -1  0.225 0.000 0.000 30.901 0.119 47.750 
27 0 -1 0 0  0.192 1.710 0.000 31.146 0.161 40.560 
28 1 0 0 0  0.185 1.960 0.000 25.938 0.095 42.270 
29 0 0 0 -1  0.231 1.430 0.000 28.576 0.102 40.670 
30 -1 1 1 1  0.230 1.880 6.440 28.282 0.080 41.100 
Where X1, X2, X3, X4 are the independent variables antioxidant (ascorbyl palmitate), emulsifier 
(soy lecithin), storage time (months) and flaxseed oil (% ingredients), respectively. Y1, Y2, Y3, 
Y4, Y5 and Y6 are responses water activity (aw), lipid separation (mm), peroxide value (mEq/ kg 
fat), hardness (N), moisture content (%wb), and Vitamin C content (mg), respectively. 
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Table 10. Estimated coefficients of the fitted quadratic equation for different responses based 
on t-statistic. 
Coefficients* Y1 Y2 Y3 Y4 Y5 Y6 
Intercept 0.215 -0.498 1.408 34.462 0.146 42.948 
X1 2.616 22.095 -64.235 -100.753 -1.91 -156.180 
X2 0.039 0.935 -3.527 1.088 0.000 15.538 
X3 -0.016 0.719 -0.256 -2.517 0.000 -3.699 
X4 -0.011 -0.021 -0.154 0.388 0.000 -0.114 
X12 -0.546 -14.018 3.412 NS -0.215 33.571 
X13 0.096 -2.247 -2.054 NS 0.014 -12.530 
X14 -0.015 0.295 -1.233 NS 0.267 -4.411 
X23 0.000 -0.109 -0.093 NS 0.000 0.623 
X24 0.001 0.005 -0.056 NS 0.000 0.212 
X34 0.000 -0.001 0.113 NS 0.000 -0.040 
X1
2 -78.316 -158.432 2416.837 NS NS 5669.979 
X2
2 -0.017 -0.404 1.895 NS NS -10.055 
X3
2 0.002 -0.044 0.053 NS NS 0.400 
X4
2 0.001 0.001 0.019 NS NS 0.006 
R2 0.754 0.907 0.928 0.737 0.404 0.843 
*Where X1, X2, X3, X4 are the independent variables antioxidant (ascorbyl palmitate), 
emulsifier (soy lecithin), storage time (months) and flaxseed oil (% ingredients), respectively. 
Y1, Y2, Y3, Y4, Y5 and Y6 are water activity (aw), lipid separation (mm), peroxide value (mEq/ 
kg fat), hardness (N), moisture content (%wb), and vitamin C content (mg), respectively. 
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Figure 16. Process flowchart for preparation of Indian LNS. 
 
1 Hot air forced convection toasting of flours (chickpea and soy flour) at 110 °C for 120 min 
2 Dry mix contains toasted chickpea flour, toasted soy flour, non-fat/ skimmed milk powder, sugar, 
cocoa powder, maltodextrin and vitamin mineral mix 
3 Lipid mix contains soybean oil, coconut oil, ghee, soy lecithin emulsifier, shortening (palm oil) 
and flaxseed oil 
4 Packaged in three layer minipouches (PAKVF4), heat sealed under nitrogen (99.99% purity) 
using equipment MVS 31 – XP at conditions vacuum 50%, gas ratio 20% and time 2.5 seconds 
5 Pouches were stored in hot air incubators (Precision by Thermo Scientific) held at 40±2 °C for 
six months 
Weighing of ingredients
Preparation of fat 
mix3
Flour toasting 1
Preparation of Dry 
mix 2
Blending
(3 minutes)
Addition of fat mix 
to blender
Blending
(3 minutes)
Scraping and 
blending
(2 minutes)
Packaging 4 
Storage 5
Final product ready 
for packaging 
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Figure 17. Response surface plots for peroxide value and lipid separation. A) Peroxide value 
(mEq/kg) of LNS showing interaction of storage time (months) and flaxseed oil (% ingredients), in 
which the following values were kept constant: antioxidant (0.01%) and emulsifier (1%). B) Lipid 
separation value (mm) of LNS showing interaction of storage time (months) and soy lecithin content 
(% ingredients), in which the following values were kept constant: antioxidant (0.01%) and flaxseed 
oil (5%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 18. Effect of accelerated storage (40 °C) on (A) water activity (Aw), (B) moisture content 
(%db), (C) hardness (N), and (D) vitamin C (mg/100g LNS) of LNS. Data points with different 
letters indicate significant differences (p≤0.05). 
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Figure 19. Consumer acceptability test (Hedonic scale 0-9) of several nutrition supplement 
products among (A) women (n=25) and (B) students (n=86). Box plots represent percentiles and 
medians. Floating bars with different letters indicate statistical differences after ANOVA and post 
hoc mean (not median) analyzes (p ≤ 0.05). 
A 
 
B 
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Chapter 4: Effect of Oregano Essential Oil and Carvacrol on Cryptosporidium parvum 
Infectivity in HCT-8 Cells 
 
4.1 Abstract 
Background: Cryptosporidium parvum is the second leading cause of persistent diarrhea among 
children in low-income settings.  
Objective: This study examined the effect of oregano essential oil (OEO) and carvacrol (CV), on 
prevention of C. parvum infectivity in vitro.  
Methods: HCT-8 cells were seeded (1×106) in 96-well microtiter plates until confluency. Cell 
viability and infectivity were assessed by seeding HCT-8 cell monolayers with C. parvum oocysts 
(1×104) in two modalities: 1) 4 h co-culture with bioactive (0–250 μg/mL) followed by washing 
and incubation (48 h, 37°C, 5% CO2) in bioactive-free media; and 2) 4 h co-culture of C. parvum 
oocysts followed by washing and treatment with bioactive (0–250 μg/mL) during 48-h incubation. 
Cell viability was tested using Live/Dead™ assay whereas infectivity was measured using C. 
parvum-specific antibody staining via immunofluorescence detection.  
Results: Loss of cell viability (~90%) was found at 125 μg/mL and 60 μg/mL for OEO and CV, 
respectively. Neither OEO nor CV modulated the invasion of C. parvum sporozoites in HCT-8 
cells. Treatment with bioactive after invasion reduced relative C. parvum infectivity in a dose-
dependent manner to 55.6 ± 10.4% and 45.8 ± 4.1% at 60 and 30 μg/mL of OEO and CV, 
respectively.  
Conclusions: OEO and CV are potential bioactives to counteract C. parvum infection in children. 
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4.2 Introduction 
Intestinal parasitic infection is considered a global public health problem by the World 
Health Organization (WHO), afflicting 3.5 billion people and causing clinical morbidity to 
approximately 450 million people globally (WHO, 1998). Although it affects all ages and socio-
economic status, parasitic infections are more prevalent in children (<5 years) living in low-income 
settings, owing to inadequate sanitation, hygiene, and healthcare system and their less developed 
immune systems (Scrimshaw, 1994). These infections alter the epithelial integrity and weaken the 
immune system in children resulting in reduced nutrient digestion and absorption, chronic gut 
inflammation, iron deficiency anemia, protein-energy malnutrition, and reduced growth and 
cognitive development (Katona and Katona-Apte, 2008). 
Common parasites responsible for morbidity and mortality in children are helminths such 
as Ascaris lumbricoides (roundworm), Trichiuris trichiuria (whipworm), Ancylostoma duodenale, 
and Necator americanus (hookworms) and protozoans such as Giardia intestinalis, Entamoeba 
histolytica, Cyclospora cayetanensis, and Cryptosporidium spp. After rotavirus, Cryptosporidium 
spp., mainly C. parvum (zoonotic) and C. hominis (anthroponotic), are the second largest cause of 
diarrheal disease and death in infants, posing 2 to 3 times higher risk of mortality (Kotloff et al., 
2013). These parasites follow a fecal-oral route of transmission. C. parvum oocysts are excreted 
in the feces of an infected host and are protected by a thick wall resistant to environmental factors 
and to most disinfection processes, making them highly resilient (Smith et al., 2005). The infection 
starts with the release of sporozoites from oocysts in the intestinal tract where they attach to and 
invade mucosal epithelial cells. In these cells, the entire endogenous development including 
asexual reproduction, gametogony and oocyst formation occurs (Tzipori, 1988). C. parvum does 
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not multiply outside of the host and completes all stages of its development (asexual and sexual) 
within a single living host. Thus far, in vitro models can only replicate the asexual cycle. Although 
cryptosporidiosis is self-limiting in healthy individuals, the infection can be life threatening among 
undernourished children with compromised immune systems.  
There are a few compounds with some, albeit limited, anticryptosporidial activity including 
paromomycin, nitazoxanide, azithromycin in combination with paromomycin, roxithromycin, and 
protease inhibitors often used in highly active antiretroviral therapy (Gargala, 2008). Currently, 
only one FDA-approved, moderately effective drug, nitazoxanide (Alinia®) (Miyamoto and 
Eckmann, 2015), is available for treatment of Cryptosporidium infection. Due to increasing 
resistance and severity of side effects, new alternative bioactives are currently under examination 
(Anthony et al., 2005).  
Oregano Essential oil (OEO), also known as the Mediterranean miracle, Sathra in 
Ayurveda or Himalayan Marjoram in India, is known to possess antibacterial, antiviral, antifungal, 
antiparasitic and antioxidant activities (Burt, 2004). The principal components responsible for the 
bioactivity of OEO are the small phenolic compounds carvacrol (CV) and thymol (Burt, 2004). 
Although there is vast literature available on the activity of OEO and its constituents against 
bacteria, limited evidence exists on its efficacy and effectiveness against gut parasites, specifically 
Cryptosporidium spp. (Burt, 2004; Sivropoulou et al., 1996).  
The objective of this study was to systemically examine the effect of OEO and its main 
monoterpene, CV, on the prevention of Cryptosporidium parvum invasion and infectivity using 
the HCT-8 cell model. 
 
74 
 
4.3 Materials and methods 
 Materials. OEO (Origanum vulgare) was obtained from Oregano World, Hollywood, 
FL. Carvacrol (98% pure, 2-methyl-5-[1-methylethyl] phenol, liquid, M≈ 150.2 g/mol, log 
extinction coefficient 3.262), Pyrazolopyrimidine 1 (PP1; positive control), RPMI 1640 medium, 
normal goat serum and sodium pyruvate were procured from Sigma-Aldrich (St. Louis, MO). 
Antibiotic-antimycotic and trypsin/EDTA were purchased from Gibco (Thermo Fisher Sci., 
Waltham, MA). Fetal Bovine Serum (FBS) and Sporo-Glo™ were obtained from Bio-West 
(Riverside, MO) and Waterborne Inc. (New Orleans, LA), respectively. 
 Preparation of C. parvum oocysts. Propagation, collection, and purification of C. 
parvum oocysts were conducted as previously described (Johnson et al., 2004; Schmidt and 
Kuhlenschmidt, 2008). Briefly, oocysts were purified from homogenized, sieved feces by 
Sheather’s sugar flotation and continuous sucrose density gradient centrifugation. Oocysts were 
washed and stored at 4°C in 50 mM Tris buffer, pH 7.2 with 10 mM EDTA. Oocysts were used 
within 1 to 2 weeks of initial isolation from stored feces when viability remained above 80% as 
judged by excystation. All procedures involving animals were part of protocols approved by the 
University of Illinois Institutional Animal Care and Use Committee (IACUC). 
 HCT-8 cell culture. Human colon adenocarcinoma (HCT-8) cells obtained from ATCC 
(CCL244) were cultured in complete medium (RPMI 1640), supplemented with 2 g of sodium 
bicarbonate per liter, 2.5 g of glucose per liter, a final concentration of 10% FBS, 5 mL antibiotic-
antimycotic solution, and 5 mL sodium pyruvate. Dissociating solution (2 mL; 0.25% 
Trypsin/EDTA) diluted with sterile PBS was used to subculture the cells in T-75 flasks, following 
incubation at 37°C and 5% CO2 for 15 min. Cells were used to seed 96-well plates for invasion 
and infectivity assays after grown to confluence within 2-3 days.  
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 HCT-8 cell viability. Two-color dual parameter Live/Dead® cell viability assay 
(Thermo-Fisher Sci.) was used to assess the viability of cells after treatment with OEO and CV at 
different concentrations (0, 7, 15, 30, 60, 125, 250, 500 and 1000 µg/mL). Live cells were 
distinguished through the intracellular esterase activity. The green and red fluorescence were 
detected under phase contrast microscope using common green and red imaging filters used with 
FITC and Texas Red. HCT-8 cell viability assay was also conducted for both modalities to observe 
the viability after 4-h cell invasion assay and after 48-h growth inhibition assay. Secondary 
confirmation of cell viability was made through microscopic observation of cell deformations and 
damage at different concentrations.  
 C. parvum invasion and growth inhibition assay. The experimental design was based 
on previous studies for in vitro inhibition of parasitic invasion (modality 1) and infection (modality 
2) of human cells using bioactives (Johnson et al., 2004). Two modalities were utilized to conduct 
the experiment as described below and shown in Figure 20. In either modality, plates with 
confluent monolayers of HCT-8 cells (1×106 cells/well) were used. Oocysts (0.5 mL, 5×104) were 
separately bleached with 40% NaOCl to facilitate oocysts excystation in situ on the cell monolayer. 
A positive control consisting of samples treated with PP1 was used at a level of 1.5 µM (0.179 
μg/mL) to inhibit ~98% C. parvum infection with no effect on cells. Two empty wells were 
maintained between each concentration treatment horizontally and vertically to avoid cross 
contamination due to the volatile nature of the bioactives. 
Invasion inhibition assay. In modality 1, oocysts (0.1 mL, 1×104) and cells were co-cultured in 
complete medium (0.2 mL, triplicate) containing several doses (0, 7, 15, 30, 60, 125, 250 µg/mL) 
of OEO or CV and incubated for 4 h at 37°C (Figure 20). This was followed by rinsing the cell 
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monolayers three times with PBS and reconstitution with bioactive-free media and 48 h incubation 
at 37°C and 5% CO2. 
Growth inhibition/infection assay. In modality 2, oocysts (0.1 mL, 1×104) and cells were co-
cultured in complete medium (0.2 mL, triplicate) and incubated for 4 h at 37°C and 5% CO2. Then, 
cells were washed with PBS three times followed by addition of 0.2 mL of several doses (same as 
before) of freshly prepared OEO or CV diluted in complete medium (Figure 20). Incubation 
continued for 48 h with or without complete medium replacement containing a fresh preparation 
of bioactives after 24 h. 
Immunodetection. At the end of the growth inhibition assay, the medium was removed and the 
cells were fixed with methanol:acetic acid solution (9:1 v/v) for 2 min. Cells were rehydrated, 
permeabilized by two consecutive rinses with PBS containing 0.1% Triton X-100, blocked with 
5% normal goat serum, and stained with Sporo-Glo™ overnight at 4°C. Infectivity was assessed 
via immunofluorescence detection using phase contrast/fluorescent microscopy after rinsing twice 
with PBS, followed by imaging in water with a 20X objective as described previously 
(Kuhlenschmidt et al., 2016). Infected cells containing replicating parasites appeared as 
fluorescent clusters of infectivity or foci. The numbers of fluorescent particles within each focus 
per 20X field were determined by an automatic microscopic collection of nine fields per well of a 
96-well plate. These nine fields were assembled into a single montage image for each well, 
representing 75% of the surface area of each well. The number of fluorescent particles in each 
montage was determined with Image J software, NIH, Bethesda, MD and expressed in fluorescent 
focus units (FFU). In both modalities, relative C. parvum growth was calculated at the doses 
described for each treatment dose using the control wells as 100% growth.  
77 
 
 Carvacrol quantification. Quantification of CV in OEO was conducted via reverse 
phase HPLC with UV detection, which consisted of a Water 600 delivery system, 717plus 
autosampler, and 996 PDA detector (Milford, MA). Separation was conducted with a C18 
Phenomenex Gemini column (5 µm, 150x4.6 mm; Torrance, CA) and an isocratic mobile phase 
(100% MeOH). Concentrations were estimated with an external standard curve for pure CV.  
 Statistics. All the experiments were conducted in triplicates, and the results were 
reported as mean ± SD. Data analysis was performed using SAS® software (SAS Institute Inc., 
Cary, NC, USA). Differences between variables were tested for significance by one-way ANOVA. 
If the model was significant, post hoc mean analysis test (Tukey's Honest Significant Difference) 
was performed. Statistical significance was established at P<0.05.  
4.4 Results 
 Cell viability. In modality 1, after the 4 h exposure of HCT-8 cells to various 
concentrations of OEO and CV, no cell death or alteration in cell texture was observed as assessed 
by Live/Dead® cell viability assay and phase contrast microscopic observations, respectively. 
Whereas, in modality 2, small but significant deformation of cell monolayer and loss of cell 
viability was observed starting at 60 µg/mL CV (5.55 ± 0.72% HCT cell death; p<0.05), and no 
changes in cell viability were observed in cells treated with OEO at doses as high as 125 µg/mL 
(Figure 21). Treatment with both OEO and CV at doses greater than 250 µg/mL resulted in 
complete loss of cell viability. Thus, the working concentrations to conduct invasion and 
infectivity studies were 7, 15, 30, 60, 125 µg/mL for OEO and 7, 15, 30, 60 µg/mL for CV.  
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Invasion inhibition assay. Relative C. parvum growth in cell culture was quantified using 
immunofluorescence assays. None of the bioactives at any of the tested doses affected the invasion 
or oocyst excystation of C. parvum on HCT-8 cells (Figure 22) during the 4h exposure (p>0.05). 
 Growth inhibition assay. Both, OEO and CV inhibited (p<0.05) C. parvum growth in 
a dose-dependent manner (Figure 22). C. parvum growth relative to the untreated control was 
reduced to 55.6 ± 10.4% at 60 μg/mL OEO and 45.8 ± 4.1% at 30 μg/mL CV, without any apparent 
toxicity to the HCT-8 cells (>97% live). Complete growth inhibition was observed with the 
positive control (PP1) at a concentration of 1.5 µM (0.179 μg/mL) with no observable cell death 
(Figure 21). Both bioactives were more effective (p<0.05) in inhibiting C. parvum infectivity after 
replacement with fresh treated media 24 hours after incubation. Figure 23 shows the relative C. 
parvum growth at the representative doses of 60 and 30 μg/mL for OEO and CV, respectively. 
 HPLC Analysis. Carvacrol concentration in OEO was 594.6 ± 10.0 µg/mL. 
 
4.5 Discussion 
C. parvum, a monoxenous apicomplexan mucosal parasite, has gained wide recognition 
due to its association with a severe diarrheal disease that affects mostly infants and children who 
are immunocompromised and undernourished. Of the large scale of compounds tested for 
antiparasitic activity against C. parvum, only a few have been found to reduce its infectivity 
(Gargala, 2008). Plant bioactive compounds have a long history of use for prevention and 
treatment of various human and animal parasitic infections (Kayser et al., 2003). Natural 
bioactives such as ferulic acid and curcumin from turmeric (Shahiduzzaman et al., 2009), a series 
of aurones and 4-methoxy-alpha-pyrones (Kayser et al., 2001), and garlic oil (Sreter et al., 1999; 
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Gaafar, 2012), are reported to have activity against Cryptosporidium spp. in vitro and in vivo. OEO 
and CV are increasingly acknowledged as having antimicrobial and antiparasitic activities (Burt, 
2004). In the Ayurvedic and other ethnopharmacological literature, OEO has been used as a 
Krumighna karma or antiparasitic agent (Lad and Frawley, 1986); however, the evidence on the 
potential role of OEO or CV against parasitic infection is limited (Table 11). 
In this study, we show a dose-dependent inhibition effect of OEO and CV on C. parvum 
infectivity (modality 2), but not invasion (modality 1) of HCT-8 cells. These effective 
concentrations of 30 μg/mL CV and 60 μg/mL OEO with relative C. parvum % growth of 
45.8±4.1% and 55.6±10.4%, respectively, were similar to those reported for other parasites as 
listed in Table 11. Application of fresh treatments after 24 hours, similarly as reported by 
Shahiduzzaman et al. (2009), was found to improve the efficacy of OEO and CV against C. parvum 
in vitro. The high variability in the data could be explained by interexperimental variation of host 
cell monolayer susceptibility to infection (Rochelle et al., 2002). 
The increase in HCT-8 cell death (dead cell % area >2%) with increased dose (CV>30 
µg/mL and OEO>60 µg/mL) in modality 2, might be due to a profound increase in the production 
of reactive oxygen species (ROS) and caspase-3 inducing apoptosis (Liang et al., 2013). Essential 
oils are known to permeabilize and depolarize the mitochondrial membranes in eukaryotic cells 
by reducing the membrane potential, affecting the ionic Ca+2 cycling, and reducing the pH gradient 
to impact the proton pump and ATP pool (Suntres et al., 2015). These processes ultimately result 
in leakage of oxygen radicals, cytochrome C, calcium ions and proteins leading to a pro-oxidant 
status and inducing apoptosis and necrosis of cells (Bakkali et al., 2008). This is consistent with 
our microscopic observations on cell deformation and damage observed at concentrations >125 
and 60 µg/mL for OEO and CV, respectively.  
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Limited literature exists on the mechanism of antiprotozoal effect of OEO or CV. The drug-
resistant properties of C. parvum are very different from other apicomplexan parasites due to its 
unique biology, distinct structure, and biochemical composition. This resilient characteristic is due 
to its intracellular but extracytoplasmic shelter that creates a parasitophorous vacuole separating it 
from the cytosol by a feeding organelle (Griffiths et al., 1998). Monoterpenes such as CV can 
modify the calcium-dependent protein kinase 1 (CDPK1) and affect the Ca2+ mediated signaling 
of the parasite, which is required for invasion, differentiation and regulation of other vital functions 
(Nagamune et al., 2008; Murphy et al., 2010). In addition, the hydrophobicity (Burt, 2004) and 
presence of hydroxyl groups in CV and thymol (Ultee, Bennik, & Moezelaar, 2002), may allow 
the phenols to penetrate the cell membrane and reduce parasitic infection by modulating 
cytoplasmic metabolic pathways such as ATP synthesis (Turina et al., 2006; Santoro et al., 2007). 
C. parvum relies solely on the host for nutrient acquisition (cholesterol) and for isoprenoids 
(intermediate isopentenyl pyrophosphate) precursors, which are required for protein prenylation, 
geranylgeranylation, N-glycosylation, and ubiquinone biosynthesis for parasite growth (Imlay and 
Odom, 2014; Ehrenman et al., 2013). Essential oil monoterpenes such as linalool, similar in size 
and structure to CV, are reported to inhibit 3-hydroxy-3-methyl-glutaryl-Co-enzymeA (HMG-
CoA) reductase, which is the key regulatory enzyme in isoprenoid synthesis via the Mevalonate 
pathway in the host cells. This, in turn, limits the acquisition of isoprenoid precursors from the 
host and blocks the growth and development of Cryptosporidium spp. (Bessoff et al., 2013). 
This study is part of our long-term goal to explore the role of bioactives in health, especially 
by incorporating them into foods to improve their functionality. Although, the results of this in 
vitro study are not conclusive as to the effective dose (i.e., EC50) due to the narrow safety window 
and obvious HCT-8 cell cytotoxicity at high concentrations, the authors contend this work provides 
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evidence of the bioactivity of small phenolic molecules and instigates the need for further research. 
Extrapolating these toxicity and efficacy effects to in vivo conditions is difficult due to the 
continuous flow of fluids through the gastrointestinal tract and the rapid metabolism of CV in 
living organisms (Atanasov et al., 2015). Other parameters such as absorption, distribution, 
metabolism and excretion (ADME), as well as permeability and solubility of OEO and CV also 
influence their bioefficacy in vivo. Previous ADME studies in rats showed rapid metabolism and 
urinary excretion of CV. Plasma Cmax (maximum plasma concentration) for CV was reached at 0.5 
h, in which a small amount of metabolites, such as glucuronide and sulfate conjugates and 
oxidation derivatives of benzyl alcohol and 2-phenylpropanol were excreted at 24 h. This was 
followed by complete disappearance of metabolites at 48 h after oral administration (Beck et al., 
2010; Austgulen et al., 1987). Furthermore, dose exposure time in vivo might be much lower than 
that used in cell in vitro models. In the HCT-8 cell model, for instance, the exposure time was 48 
h, with or without medium replacement after 24 h. Toxicological information for OEO or CV is 
limited; however, OEO was found to be non-toxic in humans at a dose of 600 mg in emulsified oil 
(Force et al., 2000). In addition, the Natural Health Products Directorate of Canada established the 
safe limit for CV as an oral medicinal ingredient at 2.7 mg/kg body weight per day for adults. This 
dose is a 100-fold higher than that found to be cytotoxic in this study. 
Although the results from this study are promising, there are some limitations. The 
immunodetection of infectivity using phase contrast/fluorescent microscopy is not as 
comprehensive and efficient as polymerase chain reaction techniques for quantification purposes. 
The in vitro model used was limited to those concentrations tolerable by the HCT-8 cells. 
Moreover, the extent to which this model has clinical relevance has to be evaluated. Nonetheless, 
the HCT-8 cell line model for cultivation of C. parvum and determination of infectivity is reported 
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to be an effective and adequate alternative to animal models (Rochelle et al., 2002; Upton et al., 
1994). The in vitro model has been critical in the identification of other bioactive compounds 
currently used in the treatment of protozoans-related diseases (Gargala et al., 2000). We 
recommend further in vivo testing in suitable animal models to provide basic pharmacological and 
toxicological data followed by controlled human clinical trials. 
 
4.6 Conclusion 
The present study supports the role of OEO as an anticryptosporidial agent. To our 
knowledge, this is the first study to demonstrate the bioactivity of both OEO and CV as inhibitors 
of C. parvum infection in HCT-8 cells. Studies should continue with the characterization of these 
and similar compounds in terms of their mechanisms of action in vitro and in pre-clinical and 
clinical models. Although our work shows the therapeutic potential for OEO and CV as 
antiparasitic agents, more research is needed to determine the effective dose of bioactives, 
establishing mechanisms of action, and elucidating their possible use in food-based applications. 
Such studies will contribute to our limited knowledge of the use of OEO and CV in foods to treat 
parasitic infections and will expand our ability to address one of the immediate causes of 
undernutrition in low-income countries.  
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4.7  Table and Figures 
Table 11. Literature on activity of oregano essential oil (OEO) and carvacrol (CV) against 
parasites. 
1. Force et al., 2000, 2.Santoro et al., 2007, 3Pensel et al., 2014, 4Giannenas et al., 2003, 5Katiki et 
al., 2014, 6Escobar et al., 2010 
Bioactive Parasite Dose and Effect Model 
OEO1 Blastocytis 
hominis, 
Entamoeba 
hartmanni, and 
Endolimax nana 
600 mg of emulsified oil for 6 
weeks resulted in disappearance 
of these parasites in stool 
specimens 
Human adults 
(n=14) 
OEO2 Trypanosoma 
cruzi 
Essential oil IC50/24 h (µg/mL) = 
175 for inhibition of epimastigote 
growth; 115 to induce 
trypomastigote lysis 
In vitro incubation in 
LIT (for 
bloodstream 
tryptomastigote) and 
RPMI-1640 (for 
epimastigote) 
medium 
OEO3 Echinococcus 
granulous and 
proloscoleces 
cysts 
Essential oil (10 µg/mL of 
thymol) resulted in complete loss 
of protoscolex viability after 72 
days post incubation 
In vitro 
incubation in 
medium 199 
OEO4 Eimeria tennella 300 mg/kg body weight 
Resulted in body weight gains 
and reduced bloody diarrhea 
Broiler chickens 
infected with 5×104 
sporulated oocysts 
CV and 
Thymol5 
Nematode 
Haemonchus 
cotortus 
LC50 fiducial limits (mg/mL)= 
Thymol: 0.13; CV: 0.11; 
both: 0.037 
In vitro egg hatch 
test 
CV and 
Thymol6 
Trypanosoma 
cruzi 
epimastigotes, 
Trypanosoma 
cruzi amastigotes 
Leishmania 
chagasi 
promastigotes 
IC50 (µg/mL) for  
Epimastigotes = CV: 3.0, 
Thymol: 0.33 
Amastigotes = CV: 27.3, Thymol: 
3.2  
Promastigotes = CV: 0.33, 
Thymol: 65.2 
Vero and THP-1 
cells 
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Figure 20. Schematic of in vitro assessment of C. parvum growth and invasion. In modality 1, 
oocysts and excysting sporozoites are exposed to different dosages of OEO or CV. In modality 2, 
sporozoites (trophozoites) attached or permeated in HCT-8 cell monolayers, undergoing asexual 
division into merozoites, are exposed to different dosages of bioactive. 
 
 
 
 
 
 
 
Modality 1. 4-h co-culture with OEO or 
CV during invasion. 
Modality 2. After 4-h invasion, 
treatment with OEO or CV during 
infection.  
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Figure 21. Images of Live (green)/ dead (red) cell assay (A) at various concentrations of oregano essential oil (OEO) and carvacrol 
(CV) and Immunofluorescence staining (B) of control (no treatment), positive control (Pyrazolopyrimidine (PP1), 100% effective dose), 
and representative dose of 60 µg/mL OEO and 30 µg/mL CV with 56% and 46% relative C. parvum growth, respectively, compared to 
the control wells. 
 
B     
 
 
Control (0 µg/mL) 
 
PP1 (1.5 µM/ 0.179 μg/mL) 
 
OEO (60 µg/mL) 
 
CV (30 µg/mL) 
 
A        
OEO 
       
CV 
       
 0 μg/mL 7 μg/mL 15 μg/mL 30 μg/mL 60 μg/mL 125 μg/mL 250 μg/mL 
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Figure 22. Effect of OEO (A) and CV (B) on relative C. parvum % growth at various doses (0, 7, 
15, 30, 60, 125 µg/mL of OEO and 0, 7, 15, 30, 60 µg/mL of CV) determined by 
immunofluorescent assays. Values are means ± standard deviation of two replicates from three 
repeated trials. *Cell death different from other points. a<b<c modality 2 only, difference among 
treatments, P<0.05 
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Figure 23. Effect of OEO and CV on relative C. parvum % growth at representative dose of 60 
µg/mL OEO and 30 µg/mL CV with or without complete medium replacement containing a fresh 
preparation of bioactives after 24 h, during the 48 h incubation. Values are means ± standard deviation 
of two replicates from three repeated trials. *difference between treatments, p<0.05.  
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Chapter 5: Functionalization of Lipid-based Nutrient Supplement with β-Cyclodextrin 
Inclusions of Oregano Essential Oil: Preparation, Characterization and Sensory 
Evaluation 
 
5.1 Abstract 
Background: Intestinal parasitic infection is one of the main causes of acute undernutrition in 
children. It alters the intestinal membrane integrity, induces inflammation, undermines nutrient 
absorption, and causes diarrheal nutrient losses. Oregano essential oil (OEO) is known to reduce 
intestinal parasitic infections when consumed orally, however, no study exists on their use as an 
ingredient in lipid-based nutrient supplement (LNS) formulations. OEO is certified GRAS by FDA 
for food use; however, its therapeutic use as a supplement has been limited due to its unpleasant 
flavor, high volatility, and instability to heat and during digestion, all which reduce its 
effectiveness against intestinal parasites.  
Objective: The objective of this study was to develop a functional LNS containing OEO, which 
is stable, acceptable and provides targeted intestinal delivery of bioactive. 
Methods: β-cyclodextrin (β-CyD) inclusion complexes of OEO (β-CyD-OEO) and carvacrol (β-
CyD-CV) (1:1 molar) were prepared using slurry complexation (-20°C) method and characterized 
based on encapsulation efficiency, moisture content, morphology, and 2-phase in vitro digestion 
stability. Carvacrol (CV) content was measured using reverse phase HPLC-UV. LNS containing 
β-CyD-OEO (27.2 mg encapsulate/ 20 g LNS) was formulated using Indian staples and 
ingredients. Discriminatory sensory tests (triangle) were performed with college students (n=58) 
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and low-income women (n=25), with young children at home (1-6 years), living in Mehsana, India 
to evaluate differences between LNS with and without bioactive ingredient (β-CyD-OEO only). 
Results: Moisture content of the dried complexes ranged from 9.1 to 9.7% d.b. and water activity 
ranged from 0.35 to 0.412. The complex sizes of β-CyD-OEO and β-CyD-CV were 1.5-7 μm and 
4-20 μm, respectively. The encapsulation efficiency was 86.04±4.48% and 81.39±3.34 for β-CyD-
OEO and β-CyD-CV, respectively, and the CV content of OEO was 0.6 g/mL. The β-CyD-OEO 
and β-CyD-CV complexes were stable through the gastric and intestinal phases and CV 
bioaccessibility ranged from 7.2-7.7% and 6.0-6.5%, respectively. Sensory tests with student and 
women revealed no differences (p>0.05) in color, aroma, and taste between LNS with and without 
β-CyD-OEO complexes. 
Conclusion: Functionalization of LNS with β-CyD-OEO is feasible based on in vitro stability and 
sensory studies. Future studies will address effects of functional LNS on parasite outcomes using 
pre-clinical models. 
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5.2 Introduction 
 Undernutrition is a major cause of morbidity and mortality in children under five and is 
associated with long-term consequences on the physical growth, cognitive development, 
susceptibility to infection and diseases, and economic performance (Black et al., 2008). Almost 
half of all deaths in children under 5 is attributable to undernutrition, translating into an 
unnecessary loss of about 3 million children a year (UNICEF/WHO/World Bank Group, 2016). 
According to the UNICEF, 1990 conceptual framework, the two immediate causes of 
undernutrition are inadequate dietary intake and repeated infectious diseases, such as parasitic 
infections, both of which are closely related and are found responsible for impairing the immune 
system interdependently (Hughes and Kelly, 2006; Cunnigham-Rundles, 2008). Inadequate dietary 
intake can cause sudden weight loss, growth faltering and immunity suppression, furthering the 
children susceptibility to infections and diseases. Whereas infection with enteric parasites can 
result in reduced nutrient digestion and absorption (Northrop-Clewes et al., 2001), frequent 
persistent diarrhea (Gendrel et al., 2003) and chronic gut inflammation (Wang, 2008) resulting in 
nutrient deficiency related conditions such as iron deficiency anemia (Farid et al., 1969) and 
protein-energy malnutrition (Muniz-Junqueira and Queiróz, 2002). Intestinal parasitic infections 
are endemic worldwide, and the infections are more prevalent in children (<5 years) living in low-
income settings, owing to inadequate sanitation, hygiene and healthcare system and their less 
developed immune systems (Scrimshaw, 1994). 
 Lipid-based nutrient supplements (LNS) are fortified food products, artificially high in 
energy and nutrients (protein, essential fatty acids, and micronutrients). They are widely used to 
address undernutrition under different settings such as in emergency relief efforts, food aid, school 
feeding, or day care centers (Arimond et al., 2013). LNS are reported to be effective in addressing 
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undernutrition through improvement of dietary protein quality and micronutrients. Nonetheless, 
there is a paucity in interventions that use LNS to tackle other immediate causes of undernutrition 
such as diseases from bacterial and parasitic infection, enteropathy and its characteristic chronic 
inflammation (Hughes and Kelly, 2006; Cunnigham-Rundles, 2008). Undernutrition is a multi-
etiological problem and interventions focused only on providing nutritious foods are not sufficient 
(Egger et al., 1990). 
 Oregano Essential oil (OEO), also known as the Mediterranean miracle, Sathra in 
Ayurveda or Himalayan Marjoram in India, is known to reduce intestinal parasitic infections when 
consumed orally. No study exists, however, on its use as an ingredient in LNS (Force et al., 2000). 
The principal compound in OEO is the phenolic monoterpene carvacrol (CV) (2-Methyl-5-(1-
methylethyl) phenol), which is also responsible for the bioactive properties (Can Baser, 2008). The 
major phenolics present in OEO are shown in Figure 24. Both, OEO and CV are classified as 
generally recognized as safe (GRAS) and are approved for food use (European Parliament and 
Council., 1996; EAFUS, 2006). 
 Incorporation of OEO or its constituents in food products, such as LNS is a challenging 
task due to its high volatility, instability, interaction with food ingredients, and potent flavor. These 
compounds have extremely low flavor threshold (odor threshold 2.29 μg/mL and taste threshold 5 
μg/mL). Furthermore, they evaporate easily, and decompose and oxidize during formulation, 
processing and storage due to exposure to heat, pressure, light, or oxygen (Beirão-da-Costa et al., 
2013; Hosseini et al., 2013). Moreover, their therapeutic effect against parasites might be limited 
by their rapid metabolism and instability during digestion. Thus, a small fraction of the oral dose, 
if any, reaches the lower gut, where often parasites reside (Kohlert et al., 2002; Kohlert et al., 
2000). CV was found to almost completely absorb in the stomach and proximal small intestine 
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before reaching the action site, i.e., lower intestine (Kohlert et al., 2000; Michiels et al., 2008). 
Encapsulation is a widely used technique for improving stability, controlled delivery and reducing 
the unpleasant odor and taste (Wang et al., 2009; McClements et al., 2009). The inclusion of CV 
and OEO in cyclodextrin (CyD) complexes is a unique method to overcome such problems (Szente 
and Szejtli, 2004).  
 β-Cyclodextrins (β-CyD) are cyclic oligosaccharides with seven glucose units joined by 
α-1,4 glycosidic bonds and have a singular hydrophobic cavity, due to the absence of hydroxyl 
group, which allows inclusion of hydrophobic molecules such as CV to mask the potent flavor and 
generate controlled and targeted delivery systems (Szente and Szejtli, 2004). β-CyD are certified 
GRAS, non-toxic, and have an adequate size to forming 1:1 inclusion complexes with CV at a 
high CyD/CV formation constant of 2620 M-1 (USFDA, 2001; Hirayama and Uekama, 1999; 
Kfoury et al., 2016b). β-CyD have been previously used as food ingredients in chocolate and 
mayonnaise for emulsification, grape drinks, coffee, ginseng extract, soybean lecithin for taste 
masking, and in instant tea drink for preserving flavor (Szente and Szejtli, 2004). 
 β-CyD complexes are not absorbed across the gastrointestinal tract due to their chemical 
structure (large number of hydrogen donors and acceptors), their molecular weight (>972 Da), and 
their low octanol/water partition coefficient (approx. log Po/w between less than -3 and 0) (Irie and 
Uekama, 1997; Matsuda, 1999). The release of the active compound in the lower gut is triggered 
through the fermentation and breakdown of CyD into small saccharides by the gut microflora 
(approx. 1011 – 1012 CFU/mL), especially Bacteroides, which use CyD as sole carbon source and 
stimulate the cyclodextrinase (Antenucci and Palmer, 1984). In vitro simulated digestion systems 
are widely used to assess the stability and bioaccessibility of active compounds in foods and 
microencapsulated materials (Hur et al., 2011; Flores and Kong, 2017). 
96 
 
 The aim of this research was to develop an LNS 2.0 via preparation and characterization 
of β-CyD complexes of CV and OEO, and discriminatory sensory evaluation of LNS containing 
OEO-β-CyD complex. 
 
5.3 Materials and Methods 
 Materials – OEO (Origanum vulgare) was supplied by Oregano World, FL. Carvacrol 
(98% pure, 2-methyl-5-[1-methylethyl] phenol, liquid, M≈ 150.2 g/mol, log extinction coefficient 
3.262) and carvacrol food grade (≥98%) were procured from Sigma-Aldrich (St. Louis, Mo., 
U.S.A.). Methanol and Acetonitrile were HPLC grade and purchased from Sigma-Aldrich (St. 
Louis, Mo., U.S.A.). Materials used for the in vitro digestion study were all purchased from Sigma-
Aldrich (St. Louis, Mo., U.S.A.). The filters used were 0.2 μm PTFE filter (VWR, Radnor, Pa., 
U.S.A.). Methanol was procured from Fisher Scientific, Pittsburgh, PA. β-CyD (Cavamax® W7) 
was procured from Wacker Chemie AG, Adrian, MI. LNS Ingredients – Chickpea flour (Spicy 
World, Houston, TX), soy flour (Bob’s Red Mill, Milwaukie, OR), maltodextrin (Honeyville, Inc, 
Brigham City, UT), FO (Spectrum Naturals, Inc, Melville, New York), clarified butter (ghee; 
AMUL, Anand, India), skim milk powder (Barry Farm, Cridersville, OH), soybean oil (Crisco, 
Orville, OH), coconut oil (Spectrum Naturals, Inc, Melville, New York), palm oil shortening 
(Crisco, Orville, OH), vitamin mineral mix (Watson Inc, West Haven, CT), soy lecithin (Now, 
Bloomingdale, IL), antioxidant ascorbyl palmitate (Spectrum Chemical, Gardena, CA), and cocoa 
powder (Hershey’s, Hershey, PA).  
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Methods. 
 Preparation of β-CyD inclusion complexes. A slurry complexation method modified 
from Karathanos et al., 2007 and Donovan et al., 2015 was used for the preparation of inclusion 
complexes (Figure 25). β-CyD (Cavamax® W7 Wacker Chemie AG, München, Germany)(MW 
1,134.98 g/mol) was mixed in distilled water at a 50% solids content. OEO or CV were added at 
a 1:1 molecular ratio in a 500 mL glass bottle with a lid and mixed using a magnetic stirrer for 48 
h at room temperature (25±5°C) to allow the complex formation and prevent loss of the active 
compound. The solution was centrifuged in 50 mL tubes at 3,000 RCF for 10 min at 4 °C and the 
supernatant water was decanted using a Pasteur pipette. The solid sediment was spread thinly in a 
500 mL mortar (16 cm diameter, Fisher Scientific) and placed in a vacuum desiccator 
(Scienceware® vacuum desiccator, Sigma-Aldrich) at -20°C for drying for 2-4 d. The moisture 
content of the ground powder was measured using a moisture content analyzer (HR83 Halogen 
Moisture Analyzer, Mettler-Toledo, LLC, Columbus, OH). Drying was completed when the 
powder reached a moisture content of 8-10%. Light grinding with pestle was used to break the 
particles into powder. Dried samples were stored in tightly sealed (parafilm), aluminum wrapped, 
50 mL tubes in dark cabinet at -20°C.  
 HPLC quantification of carvacrol– Separation and quantification of CV were carried 
out by reverse phase HPLC and UV detection (PDA at 275 nm) using a Waters 600 delivery 
system, 717plus autosampler and 996 PDA detector (Milford, Mass., U.S.A.). Separation was 
conducted with a Phenomenex Gemini 5 μm, C18, 110A, 150x4.6 mm column (Phenomenex, 
Torrance, Calif., U.S.A.) and an isocratic mobile phase of 100% methanol. Samples were extracted 
and diluted in DI water, and the sample size was adjusted to not exceed 1 mg/mL CV (CV 
solubility in H2O). An external standard curve of pure CV was constructed with varying 
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concentrations (5-100 µg/mL in water, under the same conditions. All samples were filtered with 
0.2 μM filters (VWR, Radnor, PA) before HPLC analysis. 
 Encapsulation efficiency. The entrapment efficiency (EE) of inclusion complexes was 
determined using a method modified from (Santos et al., 2015). 204 mg of β-CyD-CV (27 mg CV) 
or β-CyD-CV (23 mg CV) sample was dissolved in 27 mL acetonitrile and 27 mL of water for 
determination of total CV and surface adsorbed CV, respectively (Equation 2 and Equation 3). The 
samples were capped, vortexed for 5 minutes, and left for 48 h at room temperature. Next, the 
tubes were centrifuged at 3,000 RCF for 15 min to remove any CyD from the solution, leaving 
only the active compound. CV in the supernatant was estimated using HPLC as described above 
after filtering using 0.2 μM filters. The entrapment efficiency was calculated using equation 4. 
Total CV  (%)=
Total CV recovered(
µg
mL
)
CV added (
µg
mL
)
×100 
Surface CV (%)=
Surface adsorbed CV (
µg
mL
)
CV added (
µg
mL
)
×100 
EE=Total CV (%) - Surface CV (%)  
 Moisture content and water activity. Moisture content was analyzed using a Moisture 
Analyzer (HR83 Halogen Moisture Analyzer, Mettler-Toledo, LLC, Columbus, OH) and water 
activity was assessed using an Aqualab water activity meter (Aqualab 4TE, Decagon Devices Inc.). 
 LNS preparation. LNS formulations were prepared using staple ingredients from India 
as described by Gaur et al., 2017. Briefly, weighed flours were toasted at 110°C for 120 min in a 
forced convection hot air oven (Precision Scientific Mechanical Oven, Fisher Sci.). Flours were 
Equation 2 
 
 
Equation 3 
 
 
Equation 4 
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added to other dry ingredients and mixed further to prepare a dry mix (2 min). The dry mix was 
added to a wet grinder (PG503, Premier Wonder), and contents were mixed (3 min) to ensure 
homogenous mixing and size reduction. The fats and oils were brought to room temperature 
(23±2°C) and mixed in a glass bowl for 2 min. The lipid mixture was added to dry contents in a 
wet grinder and blended for 5 min. The samples were stored in air-tight glass jars at room 
temperature (23±2°C) until used. 
 In vitro digestion test. Digestive stability and bioaccessibility of CV was evaluated 
using a 2-phase digestion model simulating the gastric and intestinal phase, using a modified 
method from Dean A. Garrett et al., (1999) and Miller et al., (1981). Briefly, two enzyme solutions 
were used where Enzyme A mix consisted of pepsin (4 g/L) solution in 0.1 mol/L HCl and Enzyme 
B mix consisted of 250 mL of pancreatin (2 g/L) and bile extract (12 g/L) in 0.1 M NaHCO3. The 
enzyme mixes were prepared to simulate the gastric and intestinal phases, respectively. For 
digestive stability assessment, 27 mg CV and OEO were dissolved in 27 mL saline solution (0.9% 
NaCl) in a 50 ml tube (CV solubility ~1 mg/mL), vortexed, sonicated and stored for 3 h under 
refrigeration (5±2 °C). Next, for the gastric phase, 2 mL enzyme A was added to the mix and the 
pH was adjusted to 2.0 using a few drops of 1 M HCl. The samples were then incubated at 37°C 
in orbital shaking at 95 rpm for 1 h. For the intestinal phase, the pH was adjusted to 5.3 using a 
few drops of 0.9 M bicarbonate solution, and 9 mL of enzyme B was added with a few drops of 2 
M NaOH to bring the pH to 7.5. The tubes were then incubated for 2 more hours. Sample triplicates 
were extracted at each phase, diluted and filtered with 0.2 μM filters for analysis of CV content of 
digesta via reverse phase HPLC. The digestive stability was calculated using equation 5. 
 Bioaccessibility provides an estimate of active compound available for intestinal 
absorption by virtue of being solubilized in the continuous aqueous micellar fraction of the digesta. 
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For the bioaccessibility assessment, 204 mg (~27 mg CV) of β-CyD-CV and β-CyD-OEO, with 
or without LNS (4 g) were dissolved in 27 mL saline solution (0.9% NaCl), vortexed, and stored 
for 3h under refrigeration (5±2 °C). Next, the gastric and intestinal digestion were carried out 
similar to the digestive stability assessment method as described above. For isolation of the 
micellar fraction, the tubes at each phase were centrifuged at 3,000 RCF for 15 min, and the 
aqueous micellar fraction was carefully isolated using a Pasteur pipette. Next, the isolated micellar 
fraction was vortexed, diluted and filtered using 0.2 μM filters for CV content analysis. The 
bioaccessibility was calculated using equation 6. 
 Weights of the tubes were measured after each phase for correction by weight. DI water, 
β-CyD empty complex served as blank controls. Three measurements were taken. 
Digestive stability (%)= 
CV in digesta
Initial CV 
X 100 
Bioaccessibility (%)= 
CV in micellar fraction
Initial CV 
X 100 
 Morphology and particle. Morphology of the microcapsules was observed using a 
scanning electron microscope (SEM; FEI Quanta FEG 450 ESEM, Hillsboro, OR, U.S.A.) at 
Beckmann Institute for Advanced Science and Technology (Urbana, IL, U.S.A.). The Samples 
were dispersed on a double-stick conductive carbon substrate and were imaged in low vacuum 
with a large field detector at 15 kV at spot 3. Particle size was estimated from the SEM images 
using ImageJ software. 
 Sensory Difference Tests. Research protocols using humans were approved by the 
Institutional Review Board at the University of Illinois, Urbana-Champaign. The study was 
conducted in collaboration with Mansinhbhai Institute of Dairy and Food Technology (MIDFT), 
Equation 5 
 
Equation 6 
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Mehsana, India. 58 college students (18-24 years) and 25 women (18-45 years), with young 
children at home (1-6 years), otherwise healthy (no diarrhea, cold, or fever), were randomly 
recruited from MIDFT and within a 20 km radius from MIDFT, respectively. Written consents 
were obtained from the participants. Triangle tests were performed by the participants to evaluate 
differences between LNS with and without β-CyD-OEO, using the formulations as shown in Table 
12 (Meilgaard et al., 2007). The panelists were presented with three coded samples (~2 ± 0.5 g) in 
clear disposable sensory cups at a time and were asked to mark the odd (different) sample based 
on three criteria i.e., color, smell, and taste. The samples were maintained at 25 ± 2°C and all tests 
were performed in well-lit and ventilated rooms. Water (~25 ± 2°C), and crackers were provided 
for rinsing between the samples. All testing sessions were scheduled between 11:00 AM and 1:00 
PM. The subjects who were able to identify the different sample (correct) were given a score of 1 
whereas the others (incorrect) were given a score of 0. The total number of correct responses were 
then compared with the critical number at α=0.05, calculated using the equation 7 (Meilgaard et 
al., 2007). 
Zcritical =
k- (
1
3
) ×n
√2
9
×n
 
Where Z critical is 1.64 for α=0.05, k is the minimum number of correct responses to reject the 
assumption of “no difference,” n is the total number of participants. 
 Statistics. All the experiments were conducted in triplicates, and the results are reported 
as mean ± SD. For all analyses, determinations were made in triplicate as independent experiments. 
Data analyses were performed using SAS (SAS Institute, Cary, NC, USA). Differences between 
Equation 7 
102 
 
variables were tested for significance using one-way ANOVA. Significantly different means (P ≤ 
0.05) were separated by the Tukey's mean separation test. 
 
5.4 Results 
 CV content of OEO - The CV content of OEO was 604.45 ± 10.03 μg/mL. 
 Moisture content and water activity – Moisture content of the β-CyD-CV and β-CyD-
OEO ranged from 9.1 to 9.7 % d.b. and the water activity ranged from 0.35 to 0.412. 
 Encapsulation efficiency – The total CV, surface CV and encapsulation efficiencies β-
CyD-CV and β-CyD-OEO are listed in Table 13. The encapsulation efficiency of β-CyD-CV and 
β-CyD-OEO were 85.9 ± 2.06% and 80.9 ± 4.55%, respectively.  
 Morphology and particle size – The β-CyD complexes were non-spherical and 
rectangular in shape and their size ranged from 25-90 µm. Figure 26 shows the β-CyD empty, β-
CyD-CV and β-CyD-OEO complexes at magnification 1000X. The shape of β-CyD-CV and β-
CyD-OEO were similar to the β-CyD empty complexes; however, their size were significantly 
smaller in size of 4-20 µm and 1.5-7 µm, respectively, compared with the β-CyD empty samples. 
The smaller particles were found to adhere to the surfaces of the crystals. The complexes had 
cracks, invaginations and breaks (Figure 26). 
 In vitro digestive stability – Stability of OEO was measured in terms of CV content. 
Both CV and OEO were stable throughout the in vitro digestion process and no difference was 
observed in the percent digestive stability of CV in samples from initial, gastric, and intestinal 
phase (Figure 27). Digestive enzymes had no effect on the stability of CV or OEO (Figure 28). 
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 Bioaccessibility - Bioaccessibility of CV from LNS containing CV alone or OEO, 
ranged from 70-80% of the initial amount loaded. Bioaccessibility was not different between the 
digestion phases for LNS with CV, however, in the sample LNS with OEO the bioaccessibility 
reduced significantly (p<0.05) in the intestinal phase (Figure 29). Bioaccessibility of CV from 
samples β-CyD-CV or β-CyD-OEO was significantly lower (p<0.0001) compared to the samples 
containing free CV or OEO. Bioaccessibility of CV slightly increased (p<0.05) in the presence of 
LNS (Figure 30). 
 Discriminatory sensory studies – Both student and women participants were not able 
to discriminate (p<0.05) between the LNS samples with or without β-CyD-OEO (Figure 31).  
 
5.5 Discussion 
 To our knowledge, this is the first attempt to functionalize LNS with bioactives, such as 
CV and OEO, encapsulated in CyD to address intestinal parasitic infections in children. CyDs are 
widely used in food and pharmaceutical industry to encapsulate and improve the biological, 
chemical and physical properties of biologically active compounds, especially those derived from 
plants (Pinho et al., 2014).  The 1:1 molar ratio of host (β-CyD MW= 1,135 g/mol) to guest (CV 
MW= 150.21 g/mol) molecules was chosen because β-CyD-CV inclusions are reported to form 
stable complexes with the high formation constant of 2,620 M-1 at this stoichiometric ratio. CV is 
a hydrophobic (log P0/w = 3.64), non-polar monoterpenic phenol isomer and only one CV molecule 
interacts with the apolar cavity of CyD through van der Waals and hydrophobic interactions 
(Kfoury et al., 2016a; Szente and Szejtli, 2004).  
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 The encapsulation efficiency of β-CyD-CV complex was in agreement with that 
previously reported for β-CyD-CV complexes (Santos et al., 2015) and was similar to that for other 
phenolic complexes such as β-CyD-eugenol (Choi et al., 2009; Seo et al., 2010). Both CV and 
OEO were encapsulated effectively in β-CyD complexes as indicated by the high encapsulation 
efficiency, suggesting excellent suitability of CV for inclusion in β-CyD. This could be attributed 
to the high hydrophobicity (log Po/w = 3.64 (Ultee et al., 2002)), low solubility (1 mg/mL (Chen et 
al., 2014)), high formation constant with β-CyD (2,620 M-1 (Kfoury et al., 2016a) and small 
molecular size of CV molecule with excellent complementarity of the benzene ring.  
 The morphology and particle size of β-CyD complexes were in agreement with those 
reported for CV, linalool and citronella oil (Guimarães, Oliveira, Alves, Menezes, Serafini, de 
Souza Araújo, et al., 2015; Songkro et al., 2012; Menezes et al., 2014). The relatively larger size 
of β-CyD empty complexes could be attributed to agglomeration of β-CyD particles via hydrogen 
bonding. In the absence of a guest molecule, β-CyD tend to cluster and agglomerate due to lack of 
significant net charge on the inclusion complex particles i.e. no repulsive forces to prevent 
agglomeration (Hill et al., 2013). This is also consistent with observation of smaller particles 
attraction and adherence to the larger particles (Santos et al., 2015). The reduction in the particle 
size in the β-CyD-CV and β-CyD-OEO complexes indicated a conformational change of β-CyD 
that obstructed the agglomeration β-CyD similar to those observations reported by Guimarães et 
al., (2015) and Seo et al., (2010).  
 Encapsulated CV and OEO were stable under the simulated gastro-intestinal digestion 
conditions. This was in agreement with the observations from in vitro studies reported by Michiels 
et al., 2008, in which no degradation of CV was found in the proximal segments (gastric and jejunal 
simulations) but about 29% degradation was observed in the caecal simulation. The caecal 
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degradation reported in their study was due to the higher biocatalytic capacity of caecal bacteria 
(Michiels et al., 2008). The heat stability of OEO and CV could be explained by the high boiling 
point of OEO and its constituent CV, which is 238°C, thus losses due to volatilization were 
minimum under the in vitro temperature conditions at 37-39°C (Michiels et al., 2008). Yang et al. 
(2007) reported that CV was very stable (<10% degradation) at temperatures as high as 150°C, 
when heated in water for 30 minutes. (Yang et al., 2007).  
 Bioaccessibility of unencapsulated bioactives in the LNS matrix was relatively high 
(>60%). Although most of the CV was recovered and stable under these conditions, the lower 
bioaccessibility in the samples containing LNS was probably due to the interaction of CV with 
LNS ingredients. The ingredients included the emulsifier, fats and oils, proteins and micronutrients 
that might have promoted the migration of CV to the top lipid layer or bottom pellet of the 
centrifuged digesta resulting in incomplete micellarization (McClements and Li, 2010). This was 
in agreement with the results reported by Roman et al., (2012), in which β-Carotene recovery from 
fortified almond butter was low at all simulated stages of digestion. The authors suggested that the 
protein or carbohydrate compounds in the almond butter might emulsify or encapsulate β-carotene, 
thereby modifying its release from the food matrix. Our findings and those of Roman et al., (2012) 
require further verification using in vivo models. 
 Encapsulation of CV in β-CyD reduced its bioaccessibility (<10%) regardless of the 
presence of LNS. This indicates a limited degradation of the β-CyD by gastric or pancreatic 
enzymes under digestion conditions. This enables desired lower-gut targeted release of the CV or 
OEO through the fermentation and breakdown of CyD by gut microflora (Minami et al., 1998; 
Hirayama and Uekama, 1999). This controlled and targeted release property of β-CyD was utilized 
by Shyale et al, 2005 to develop an antiparasitic drug delivery system to target helminths residing 
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in the lower gut and to prevent the absorption of the drug in the upper gut. In that study, tablets of 
β-CyD-albendazole were developed using guar gum as a matrix carrier and were subjected to a 3-
step in-vitro drug release study, involving gastric, intestinal and a colonic phase using rat caecal 
content medium, under anaerobic conditions.  The encapsulated drug formulations, especially 
those with higher guar gum content (>30%), had a lower bioaccessibility or drug release during 
the gastrointestinal phase and a considerably higher release in the colonic phase, indicating the 
microbial fermentation and breakdown of β-CyD in the presence of rat caecal contents. Similarly, 
García-Rodriguez et al., 2001 reported β-CyD-albendazole to have higher antihelmintic activity 
compared to carboxymethylcellulose-albendazole suspension. In their study, mice were infected 
with Trichinella spiralis and both antihelmintic suspensions were delivered orally at 50 mg/kg. 
Only β-CyD-albendazole was shown to be effective due to lower gut release of the drug.  
 The increased release and thus higher bioaccessibility of CV with addition of LNS could 
be explained by the high affinity of hydrophobic lipids in LNS towards CyD complexes, which 
when dissolved in the aqueous matrix were probably able to extract and/or replace the CV from 
the hydrophobic cavity in CyD complexes as described by Saenger, (1980). 
 Encapsulation strategy also resulted in the effective reduction in the perception of 
essential oil when presented to subjects. Both groups, students and women participants were not 
able to identify (p<0.05) the odd sample. This is similar to the results reported by Kant et al, (2004), 
in which the panelist were not able to differentiate between the high fat and fat-free lemon flavored 
yogurt, when β-CyD encapsulates of lemon flavor were used for fat-free formulations. In another 
study, incorporation of β-CyD in ginseng solutions, at a level of 1 g β-CyD in 100 mL solution, 
was found to reduce the bitterness intensity, as evaluated using a descriptive sensory analysis 
(Tamamoto et al., 2010). Similarly, addition of 0.4% (w/v) β-CyD to goat milk was found to reduce 
107 
 
the goaty flavor (short chain fatty acids) as determined using a triangle sensory test (Meier et al., 
2001).  
 Although the results of this study are promising, there are some limitations. In vitro 
digestion model used in the study was limited to the gastric and intestinal digestion stages and we 
did not simulate the lower gut phase. Nonetheless, other groups have evaluated the release of 
albendazole, (Shyale et al., 2005) and biphenyl acid (Hirayama et al., 1996) incubation under 
simulated colon conditions using rat caecal contents and have found preferential drug release in 
the colonic phase due to the presence of microflora. The in vitro model used in this study was 
successful in accurately predicting the release characteristics of CV in terms of bioaccessibility in 
a static environment, however, future in vivo studies are necessary to assess such characteristics in 
the dynamic environment of the intestine.  Triangle sensory tests with inexperienced panelists are 
known to be more accurate when conducted in duplicates (i.e., each participant performs the test 
twice) (Dacremont and Sauvageot, 1997). We did not conduct the triangle test in duplicates or 
compared it with other sensory tests to increase the power of the test.  
 
5.6 Conclusions 
 Functionalization of LNS with β-CyD-OEO was technically feasible based on 
physicochemical characterization, in vitro stability and bioaccessibility, and sensory studies. 
Future studies will address the effects of functional LNS on parasite outcomes using pre-clinical 
models.  
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5.7 Tables and Figures 
Table 12. Recipe formulation for 100 g LNS with or without β-CyD-OEO 
Ingredient LNS with β-CyD-OEO 
(g) 
LNS without β-CyD-
OEO 
(g) 
Soybean oil 10 10 
Coconut oil 8 8 
Ghee 8 8 
Soy lecithin emulsifier 1 1 
Shortening (palm oil) 4 4 
Chickpea flour (toasted) 17 17 
Soy flour, full fat (toasted) 10 10 
Nonfat/skimmed milk powder 15.25 15.25 
Sugar 10 10 
Flaxseed oil 5 5 
Vitamin–mineral mix 3.75 3.75 
Cocoa powder 2 2 
Maltodextrin M100 5.6 6 
β-CyD-OEO 0.4 0 
Total 100 100 
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Table 13. CV recovery, surface CV and encapsulation efficiency of β-CyD inclusions of CV and 
OEO. 
 
Sample Total CV 
recovered (%) 
Surface CV 
(%) 
Encapsulation 
efficiency (%) 
β-CyD-CV 92.0 ± 2.2 6.11 ± 0.29 85.9 ± 2.1% 
β-CyD-OEO 88.1 ± 4.8 7.20 ± 0.59 80.9 ± 4.6% 
 
 
Figure 24. Major phenolics in oregano essential oil. 
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Figure 25. Procedure to prepare β-CyD inclusions of CV and OEO. 
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Figure 26. Scanning electron microscope images of (A) β-CyD empty complex, (B) β-CyD-CV 
and (C) β-CyD-OEO at 1000X magnification.  
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Figure 27. Stability of CV and OEO during the simulated digestion conditions. Data points 
represent means ± SD 
 
 
Figure 28. Effect of digestive enzymes on digestive stability of CV and OEO. Data points 
represent means ± SD. 
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Figure 29. Bioaccessibility of OEO and CV from LNS samples. Data points represent means ± 
SD. *statistical differences in between treatments within each digestive phase, p<0.05. 
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Figure 30. Bioaccessibility of β-CyD-CV and β-CyD-OEO in LNS under in-vitro gastro-intestinal 
digestion conditions. Data point represent mean ± SD. *statistical differences in bioaccessibility 
between LNS samples containing CV and OEO, p<0.05. 
 
Figure 31. Bioaccessibility of β-CyD-CV and β-CyD-OEO under in-vitro gastro-intestinal 
digestion conditions. Data point represent mean ± SD. *statistical differences in bioaccessibility 
between β-CyD complexes containing CV and OEO, p<0.05. 
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Figure 32. Triangle test results showing no significant differences (p<0.05) between LNS with or 
without β-CyD-OEO in students (n=58) and women (n=25) with young children at home (1-6 
years). 
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Chapter 6: Summary and Future Directions 
  
 In this dissertation study, considerable progress was made towards developing an LNS 
2.0 that could potentially address undernutrition by combining a nutrient dense supplementary 
food (i.e., LNS) with a functional ingredient that can reduce enteric parasitic infections in Indian 
children (i.e., carvacrol from OEO).  
 In the first study, LNS with staple ingredients from India fortified with FO was 
successfully formulated and optimized using RSM. A four-factor-three-level: omega-3 fatty acid 
source (flaxseed oil) (0-10%), antioxidant (ascorbyl palmitate: 0.0-0.03%), emulsifier (soy 
lecithin: 0.5-1.5%), and storage time (0-6 months) model was employed to optimize LNS’s 
functionality and storage stability. The designed LNS formulations yielded approximately 452 
kcal, 13.2 g of protein, 30 g of fat, and 53 g of carbohydrates and the optimal levels to maximize 
storage time and FO, and minimize oxidation were identified as 0.02% antioxidant, 1.5% 
emulsifier, and 4.9% FO. In addition, the newly developed LNS was found highly acceptable 
among Indian mothers and students with acceptability scores similar to those of other commercial 
supplements tested. To our knowledge, this is the first study that used RSM for LNS ingredient 
and storage stability optimization. A similar methodology could be utilized in future to optimize 
the existing or new LNS formulations, fortified with other omega-3 fatty acid sources such as fish 
oil, camelina oil, and algal oil. Also, future LNS formulations could target other at-risk populations 
such as pregnant and lactating women and elderly groups living in the low- and middle-income 
countries. Further research on the effect of omega-3 fortified LNS on growth and development of 
children is warranted.  
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 The second study of this dissertation aimed at identifying the antiparasitic, more 
specifically, the anticryptosporidial effect of OEO and CV on the invasion and infection of HCT-
8 cells using the in vitro cell culture model. Neither OEO nor CV modulated the invasion of C. 
parvum sporozoites. Treatment after invasion, however, was found to reduce relative C. parvum 
infectivity in a dose-dependent manner to 55.6 ± 10.4% and 45.8 ± 4.1% at 60 and 30 μg/mL of 
OEO and CV, respectively. To our knowledge, this was the first study to demonstrate the 
therapeutic potential of OEO and CV as anticryptosporidial agents (Gaur et al., 2016). Future 
studies on characterization of these antiparasitic agents in terms of their mechanisms of action in 
vitro and in pre-clinical and clinical models are recommended. Such studies will contribute to our 
limited knowledge of the use of OEO and CV in foods to treat parasitic infections and will expand 
our ability to address one of the immediate causes of undernutrition in low-income countries.  
 In the final study of this dissertation, the author functionalized LNS to contain CV and 
OEO, and thus, to develop an improved LNS (i.e., LNS 2.0), which could potentially address 
intestinal parasitic infections in children. This is the first example of a product aimed at addressing 
both immediate causes of undernutrition in poor settings. Functionalization of LNS with β-CyD-
OEO was found feasible based on physicochemical characterization, in vitro stability and 
bioaccessibility, and sensory studies. The inclusion of OEO in β-CyD was found successful in 
masking the potent flavor of OEO. This was indicated by the discriminatory sensory test results in 
which students and mothers of children under the age of 5 were not able to discriminate (p>0.05) 
between LNS with and without β-CyD-OEO complexes in terms of color, aroma, and taste. β-
CyD-OEO and β-CyD-CV complexes were found stable throughout the oral, gastric and intestinal 
phases with a limited release of CV in the micellar phase, which was represented by low CV 
bioaccessibility ranging from 7.2-7.7% and 6.0-6.5%, respectively. This stability and controlled 
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release characteristics are critical for the targeted delivery of OEO from LNS in the lower gut, 
where CyD are fermented and broken down by the gut microflora. Future studies are required to 
establish the in vivo controlled release characteristics of OEO from β-CyD-OEO with or without 
LNS, and to evaluate the effects of functional LNS on parasite and clinical outcomes. Other studies 
could examine the inclusion of broad spectrum antiparasitic drugs into CyD and their effects using 
pre-clinical and clinical models.   
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 Appendix A: Institutional Review Board Approval Notice 
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Appendix B: Institutional Review Board Approved Consent Form 
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Appendix C: Institutional Review Board Approved Consent Form in Gujarati 
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Appendix D: Demographic Information Questionnaire 
Please read the following questions and mark the option that represent your situation. 
1. What is your age in years? 
a)      Less than 18  
b)      18 – 24  
c)       24 – 30  
d)      30 – 45  
e)      Above 45  
 
2. What is your occupation (check all that apply)? 
a)      Farming  
b)      Cattle rearing  
c)       House wife  
d)      Office worker (factory, Anganwadi, hospital, post office, etc.)  
e)      Other  
 
3. How many children do you have? 
a)     1  
b)   2   
c)   3  
d)   4  
e)   More than 4  
 
4. What is the age of your youngest children? 
 
 
5. For the most part of the day, who feeds the younger children at home? 
a)     You  
b)   Your husband  
c)   Your older children  
d)   Your parents in-law  
a)     0 to 3 years  
b)   4 to 8 years  
c)   9 to 13 years  
d)   More than 13 years  
e)   More than 4  
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e)   Other relatives  
 
 
6. Does your family feed any supplementary food to the children? 
a)     Yes  If YES, complete the questions below 
b)   No  If NO, finish this questionnaire 
  
6. 1. If yes, what kind of supplementary food is given to children at home? 
a)     Homemade supplementary food  
b)  Commercial supplementary foods (Amulspray, Cerelac, Lactogen, 
Nestogen etc.) 
 
 
6.2.  What ingredients do you use to make supplementary food for children at home? 
Check all that apply. 
a)    Grains (e.g. rice, wheat, millet etc.)  
b)  Pulses (e.g. chana dal, urad dal, moong dal etc.)  
c)  Fat (e.g. ghee, oil, dalda etc.)  
d)  Fruits (e.g. banana, mango, apple etc.)  
e)  Sugar (e.g. white, brown etc.)  
f)  Salt  
g)  Spices (curry, oregano, etc.)  
 
 --------------------------------------------x-------------------END--------------------x---------------------------------------------- 
 
Thank you for filling the questionnaire. Please submit the form and collect the receipt. 
 
Note: The receipt contains important information on date, time and venue for test. Please bring it 
with you on the test day. 
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Appendix E: Template for Participant Receipt 
 
 
CONSUMER ACCEPTABILITY TEST 
(To be provided to the subject after signing the consent form) 
 
Unique Identification Code [insert three digit code] 
Date of Test [insert date] 
Time of Test [insert time] 
Venue [insert venue] 
  
Questions? Contact Mr. Shashank Gaur at _________________________ [local phone 
number] 
 
Authorized Signature  
Thank you for your participation! 
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Appendix F: Ballot Template for Consumer Acceptability Test 
Directions: Place the given cup in front of you and evaluate it based on the criteria below using 
the scale provided (1 to 9)  
 
Sample number: _____________ 
 
To start, look at the cup XXX and rate how much you like its COLOUR. 
COLOUR 
1 2 3 4 5 6 7 8 9 
         
 
 
 
 
 
 
 
 
 
 
 
Now, bring the sample to your nose and rate how much you like its SMELL. 
SMELL 
1 2 3 4 5 6 7 8 9 
         
 
 
 
 
 
 
 
 
 
 
 
Now, place a spoonful of product in your mouth and rate how much you like mouthfeel. 
MOUTHFEEL 
1 2 3 4 5 6 7 8 9 
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Please rate how much you like its SWEETNESS. 
SWEETNESS 
1 2 3 4 5 6 7 8 9 
         
 
 
 
 
 
 
 
 
 
 
 
Please rate how much you like its APPEARANCE 
 
 
Rate the product in terms of overall ACCEPTABILITY. 
OVERALL ACCEPTABILITY 
1 2 3 4 5 6 7 8 9 
         
 
 
 
 
 
 
 
 
 
 
 
Now, please eat the cracker provided to you. Rinse your mouth and spit in the disposable 
cup. 
       
APPEARENCE 
1 2 3 4 5 6 7 8 9 
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Appendix G: Ballot Template for Ranking Test 
 
Directions: You are presented with four cups. Taste product from each cup and rank them 
excellent, good, fair or bad based on your overall acceptability. Please use tick marks () 
 
Sample 
number 
Excellent Good Fair Bad 
453 
    
334 
    
221 
    
515 
    
 
 
 
Thank you! 
 
Please submit the forms. 
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Appendix H: Ballot Template for Discriminatory Sensory Tests (Triangle Tests) 
Please select the sample which is different based on color 
Participant no. ___________ 
 
 
 
   
 
-------------------------------------------cut here----------------------------------------------- 
Participant no. ___________ 
Please select the sample which is different based on smell 
 
 
 
   
 
 
-------------------------------------------cut here----------------------------------------------- 
Participant no. ________ 
Please select the sample which is different based on taste 
 
 
 
 
   
189 767 312 
436 
 
287 
 
754 
 
875 
 
196 
 
545 
 
